Bispecific anti-BCMA x anti-CD3 antibodies and their uses

Bispecific antibodies targeting BCMA and CD3 activate T cells to kill BCMA-expressing tumor cells, addressing the need for effective therapies in multiple myeloma and B-cell malignancies.

JP7586974B2Active Publication Date: 2024-11-19REGENERON PHARMACEUTICALS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023117208
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-01-17
Filing Date
2023-07-19
Publication Date
2024-11-19
Estimated Expiration
2039-07-18

AI Technical Summary

Technical Problem

Current therapies lack effective methods to specifically target and kill BCMA-expressing cells, such as those found in multiple myeloma and other B-cell malignancies, using a T cell-mediated approach.

Method used

Development of bispecific antigen-binding molecules that simultaneously bind to BCMA and CD3, activating T cells to kill BCMA-expressing tumor cells.

Benefits of technology

The bispecific antibodies effectively inhibit the growth of BCMA-expressing tumor cells by activating T cells, showing potential in treating multiple myeloma and other B-cell malignancies with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586974000119
    Figure 0007586974000119
  • Figure 0007586974000120
    Figure 0007586974000120
  • Figure 0007586974000121
    Figure 0007586974000121
Patent Text Reader

Abstract

To provide novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells.SOLUTION: In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the present invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and / or therapeutically beneficial. For example, the bispecific antibodies of the present invention are useful for the treatment of various cancers, including multiple myeloma.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Sequence Listing Reference This application incorporates by reference the Sequence Listing, which was created on July 8, 2019, and which has been submitted in computer readable format as File 10452WO01-Sequence, which contains 63,211 bytes.

[0002] The present invention relates to antibodies and antigen-binding fragments thereof that are specific for B-cell maturation antigen (BCMA), and methods of their use. The present invention includes bispecific antigen-binding molecules (e.g., bispecific antibodies) that bind to BCMA and CD3, and methods of their use. [Background technology]

[0003] B-cell maturation antigen (BCMA), also known as TNFRSF17 or CD269, is a type III transmembrane protein lacking a signal peptide and containing a cysteine-rich extracellular domain. BCMA, along with closely related proteins, promotes the survival of B cells at different stages of development. BCMA is expressed exclusively in B-cell lineage cells, particularly in the interfollicular regions of germinal centers, as well as plasmablasts and differentiated plasma cells. BCMA is selectively induced during plasma cell differentiation and is required for optimal survival of long-lived plasma cells in the bone marrow. In multiple myeloma, BCMA is widely expressed at high levels on malignant plasma cells, and BCMA expression increases with progression from normal cells to active multiple myeloma. BCMA is also expressed in other B-cell malignancies, including Waldenstrom's macroglobulinemia, Burkitt's lymphoma, and diffuse large B-cell lymphoma. Non-patent literature 1.

[0004] CD3 is a homodimeric or heterodimeric antigen expressed on T cells along with the T cell receptor complex (TCR) and is required for T cell activation. Functional CD3 is formed from the dimeric association of two of four different chains: epsilon, zeta, delta, and gamma. Dimeric configurations of CD3 include gamma / epsilon, delta / epsilon, and zeta / zeta. Antibodies against CD3 have been shown to cluster CD3 on T cells, thereby triggering T cell activation in a manner similar to TCR engagement by peptide-loaded MHC molecules. Thus, anti-CD3 antibodies have been proposed for therapeutic purposes, including T cell activation. Additionally, bispecific antibodies capable of binding to CD3 and a target antigen have been proposed for therapeutic uses, including targeting T cell immune responses to tissues and cells expressing the target antigen.

[0005] Antigen binding molecules that target BCMA, including bispecific antigen binding molecules that bind both BCMA and CD3, may be useful in therapeutic settings where it is desired to specifically target and T cell-mediated kill cells expressing BCMA. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Tai et al., Immunotherapy, 7(11):1187-1199, 2015. Summary of the Invention

[0007] In one aspect, the present invention provides a method for the treatment of cancer, comprising: (a) administering to a patient a therapeutically effective amount of a cancer cell comprising an EC50 antibody having an EC60 antibody of less than about 100 nM as measured by an in vitro FACS binding assay; 50 and (b) a first antigen-binding domain that specifically binds to a human B-cell maturation antigen (BCMA) on a target tumor cell, the first antigen-binding domain having a binding domain of about 10 -6 EC below M 50 Human CD3 and a second antigen-binding domain (D2) that specifically binds to

[0008] In some cases, the bispecific antigen-binding molecule is about 10 -9 EC below M 50 In some cases, the bispecific antigen-binding molecule is administered in a concentration of about 10 -9 EC below M 50 In some cases, the bispecific antigen-binding molecule mediates in vitro T cell killing of tumor cell lines expressing BCMA having about 10 -8 EC below M 50 In some embodiments, the bispecific antigen binding molecule interacts with amino acid residues 1-43 of BCMA as set forth in SEQ ID NO:115.

[0009] In some cases, the target tumor cells are plasma cells. In some cases, the target tumor cells are from a patient suffering from multiple myeloma or from another B cell disorder characterized in part by having B cells expressing BCMA. In some cases, the bispecific antigen binding molecule inhibits the proliferation of BCMA-expressing tumor cells at a dose of about 0.04 mg / kg to about 4.0 mg / kg. In some cases, the dose is 0.04 mg / kg, 0.4 mg / kg, or 4 mg / kg. In some embodiments, the dose is administered to a patient in need of administration at least twice a week for at least seven doses. In some cases, the bispecific antigen binding molecule inhibits the proliferation of BCMA+ tumor cells selected from the group consisting of myeloma cells, lymphoma cells, and leukemia cells. In some cases, the bispecific antigen binding molecule inhibits the proliferation of BCMA+ tumor cells selected from the group consisting of H929 cells, MOLP-8 cells, and OPM cells.

[0010] In some cases, the bispecific antigen-binding molecule cross-reacts with cynomolgus BCMA. In some cases, the bispecific antigen-binding molecule does not cross-react with cynomolgus BCMA.

[0011] In some embodiments, the isolated bispecific antigen-binding molecule comprises a first antigen-binding domain comprising (a) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) comprised within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 66, and (b) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) comprised within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 82. In some embodiments, the isolated bispecific antigen-binding molecule comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 68, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 70, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 72. In some embodiments, the isolated bispecific antigen-binding molecule comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 84, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 86, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 88. In some cases, the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:66 and a LCVR comprising the amino acid sequence of SEQ ID NO:82.

[0012] In some embodiments, the isolated bispecific antigen-binding molecule comprises a second antigen-binding domain comprising (a) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) comprised within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 90 or SEQ ID NO: 98, and (b) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) comprised within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 82. In some embodiments, the second antigen-binding domain comprises (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 100, (b) an HCDR2 comprising the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 102, and (c) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 96 or SEQ ID NO: 104. In some embodiments, the second antigen-binding domain comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 84, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 86, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 8 ... In some cases, the second antigen-binding domain comprises (a) an HCDR1, HCDR2, HCDR3 domain comprising the amino acid sequence of SEQ ID NO: 92, 94, 96, respectively, and an LCDR1, LCDR2, LCDR3 domain comprising the amino acid sequence of SEQ ID NO: 84, 86, 88, respectively, or (b) an HCDR1, HCDR2, HCDR3 domain comprising the amino acid sequence of SEQ ID NO: 100, 102, 104, respectively, and an LCDR1, LCDR2, LCDR3 domain comprising the amino acid sequence of SEQ ID NO: 84, 86, 88, respectively. In some cases, the second antigen-binding domain comprises (a) an HCVR comprising the amino acid sequence of SEQ ID NO: 90, and an LCVR comprising the amino acid sequence of SEQ ID NO: 82, or (b) an HCVR comprising the amino acid sequence of SEQ ID NO: 98, and an LCVR comprising the amino acid sequence of SEQ ID NO: 82.

[0013] In another aspect, the present invention provides an isolated bispecific antigen-binding molecule comprising: (a) a first antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 68, 70, 72, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively; and (b) a second antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 92, 94, 96, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively. In some cases, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 66 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82; and (b) a second antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 90 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82.

[0014] In another aspect, the present invention provides an isolated bispecific antigen-binding molecule comprising: (a) a first antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 68, 70, 72, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively; and (b) a second antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 100, 102, 104, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the sequences of SEQ ID NOs: 84, 86, 88, respectively. In some cases, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 66 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82; and (b) a second antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 98 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82.

[0015] In another aspect, the present invention provides an isolated bispecific antigen binding molecule comprising: (a) a first antigen binding domain that specifically binds human BCMA and comprises a CDR of an HCVR that comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 122, and 124, and a CDR of an LCVR that comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 82, 123, and 125; and (b) a second antigen binding domain that specifically binds human CD3. In some cases, the first antigen-binding domain comprises the CDRs from a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 122 / 123, 124 / 125, 2 / 82, 18 / 82, 34 / 82, 50 / 82, 66 / 82, 122 / 82, and 124 / 82. In some cases, the first antigen binding domain comprises an HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domain selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, 20-22-24-28-30-32, 36-38-40-44-46-48, 52-54-56-60-62-64, 68-70-72-76-78-80, 4-6-8-84-86-88, 20-22-24-84-86-88, 36-38-40-84-86-88, 52-54-56-84-86-88, and 68-70-72-84-86-88, respectively. In some cases, the first antigen-binding domain comprises a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 122 / 123, 124 / 125, 2 / 82, 18 / 82, 34 / 82, 50 / 82, 66 / 82, 122 / 82, and 124 / 82. In some cases, the second antigen-binding domain comprises the CDRs of a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 90 / 82 and 98 / 82.

[0016] In another aspect, the invention provides an isolated bispecific antigen binding molecule that competes for binding to BCMA or binds to the same epitope on BCMA as a reference antibody, said reference antibody comprising a first antigen binding domain comprising a HCVR / LCVR pair comprising the amino acid sequence of SEQ ID NO: 66 / 82 and a second antigen binding domain comprising a HCVR / LCVR pair comprising the amino acid sequence of either SEQ ID NO: 90 / 82 or SEQ ID NO: 98 / 82.

[0017] In another aspect, the present invention provides an isolated bispecific antigen-binding molecule that competes for binding to human CD3 or binds to the same epitope on human CD3 as a reference antibody, said reference antibody comprising a first antigen-binding domain comprising a HCVR / LCVR pair comprising the amino acid sequence of SEQ ID NO: 66 / 82 and a second antigen-binding domain comprising a HCVR / LCVR pair comprising the amino acid sequence of either SEQ ID NO: 90 / 82 or SEQ ID NO: 98 / 82.

[0018] Any of the bispecific antigen-binding molecules discussed above or herein can be bispecific antibodies. In some cases, the bispecific antibody comprises a human IgG heavy chain constant region. In some cases, the human IgG heavy chain constant region is of isotype IgG1. In some cases, the human IgG heavy chain constant region is of isotype IgG4. In various embodiments, the bispecific antibody comprises a chimeric hinge that reduces Fcγ receptor binding compared to a wild-type hinge of the same isotype.

[0019] In another aspect, the present invention provides a pharmaceutical composition comprising a bispecific antigen-binding molecule (e.g., a bispecific antibody) as described above or discussed herein and a pharma- ceutically acceptable carrier or diluent.

[0020] In another aspect, the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding a bispecific antigen-binding molecule (e.g., a bispecific antibody) as described above or discussed herein.

[0021] In another aspect, the present invention provides an expression vector comprising a nucleic acid molecule as discussed above.

[0022] In another aspect, the invention provides a host cell comprising an expression vector as discussed above.

[0023] In another aspect, the invention provides a method of inhibiting the growth of a plasma cell neoplasm in a subject, comprising administering to the subject an isolated bispecific antigen-binding molecule, or a pharmaceutical composition comprising the bispecific antigen-binding molecule, as discussed above or herein. In some cases, the plasma cell neoplasm is multiple myeloma. In some cases, the method further comprises administering a second therapeutic agent or treatment regimen. In some embodiments, the second therapeutic agent is an anti-tumor agent (e.g., a chemotherapeutic agent including melphalan, vincristine (Oncovin), cyclophosphamide (Cytoxan), etoposide (VP-16), doxorubicin (Adriamycin), liposomal doxorubicin (Doxil), obendamustine (Treanda), or a chemotherapeutic agent effective in treating a plasma cell neoplasm in a subject. In some embodiments, the second therapeutic agent includes a steroid. In some embodiments, the second therapeutic agent includes a targeted therapy including thalidomide, lenalidomide, and bortezomib, which are therapies approved to treat newly diagnosed patients. Lenalidomide, pomalidomide, bortezomib, carfilzomib, panobinostat, ixazomib, elotuzumab, and daratumumab are examples of second therapeutic agents effective for treating relapsed myeloma. In certain embodiments, the second therapeutic agent is a regimen including radiation therapy or stem cell transplantation. In certain embodiments, the second therapeutic agent can be an immunomodulatory agent. In certain embodiments, the second therapeutic agent can be a proteasome inhibitor including bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro). In certain embodiments, the second therapeutic agent may be a histone deacetylase inhibitor, such as panobinostat (Farydak). In certain embodiments, the second therapeutic agent may be a monoclonal antibody, an antibody drug conjugate, a bispecific antibody conjugated to an anti-tumor agent, a checkpoint inhibitor, or a combination thereof.

[0024] In another aspect, the present invention provides a method of treating a patient suffering from multiple myeloma or another BCMA-expressing B-cell malignancy, comprising administering to the subject an isolated bispecific antigen-binding molecule or a pharmaceutical composition comprising the bispecific antigen-binding molecule as described above or herein. In some cases, the BCMA-expressing B-cell malignancy is selected from the group consisting of Waldenstrom's macroglobulinemia, Burkitt's lymphoma, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Hodgkin's lymphoma. In some cases, the method further comprises administering a second therapeutic agent. In some embodiments, the second therapeutic agent comprises an anti-tumor agent (chemotherapeutic agent), a DNA alkylating agent, an immunomodulatory agent, a proteasome inhibitor, a histone deacetylase inhibitor, radiation therapy, stem cell transplantation, an immunomodulatory agent, a monoclonal antibody that interacts with an antigen expressed on the surface of a tumor cell, a monoclonal antibody other than those described herein that can interact with a different antigen on the surface of a plasma cell, a bispecific antibody with one arm that binds to an antigen on the surface of a tumor cell and the other arm that binds to an antigen on a T cell, an antibody drug conjugate, a bispecific antibody conjugated to an anti-tumor agent, a checkpoint inhibitor, such as one that targets PD-1 or CTLA-4, or a combination thereof. In certain embodiments, the checkpoint inhibitor may be selected from a PD-1 inhibitor, such as pembrolizumab (Keytruda), nivolumab (Opdivo), or cemiplimab (REGN2810). In certain embodiments, the checkpoint inhibitor may be selected from a PD-L1 inhibitor, such as atezolizumab (Tecentriq), avelumab (Bavencio), or durvalumab (Imfinzi). In certain embodiments, the checkpoint inhibitor may be selected from a CTLA-4 inhibitor, such as ipilimumab (Yervoy). Other combinations that can be used in combination with the antibodies of the present invention are described above.

[0025] In another aspect, the present invention provides a method of treating a patient suffering from a BCMA-expressing tumor, comprising administering to the subject an isolated bispecific antigen-binding molecule, or a pharmaceutical composition comprising the same, as discussed above or herein, in combination with an anti-PD-1 antibody or antigen-binding fragment thereof. In some cases, the anti-PD-1 antibody or antigen-binding fragment is an anti-PD-1 antibody. In some embodiments, the anti-PD-1 antibody is cemiplimab (REGN2810). In various embodiments, the combination of an anti-BCMA x anti-CD3 bispecific antigen-binding molecule (e.g., a bispecific antibody) and an anti-PD-1 antibody or antigen-binding fragment (e.g., an anti-PD-1 antibody) produces a synergistic therapeutic effect in treating BCMA-expressing tumors.

[0026] In another aspect, the present invention provides the use of a bispecific antigen binding molecule as described above or herein, or a pharmaceutical composition as described above or herein, in the treatment of a disease or disorder associated with expression of BCMA. Optionally, the disease or disorder is cancer. In some embodiments, the cancer is multiple myeloma. Optionally, the disease or disorder is Castleman's disease. Optionally, the antigen binding molecule is for use in combination with an anti-PD-1 antibody or antigen-binding fragment thereof, and optionally, the anti-PD-1 antibody is cemiplimab (REGN2810).

[0027] The present invention further includes the use of the bispecific antigen-binding molecule described above or herein in the manufacture of a medicament for treating a disease or disorder associated with BCMA expression. In some cases, the disease or disorder is cancer. In some embodiments, the cancer is multiple myeloma.

[0028] In various embodiments, any of the features or components of the embodiments described above or discussed herein can be combined, and such combinations are encompassed within the scope of the present disclosure. Any particular value described above or discussed herein can be combined with another associated value described above or discussed herein to recite ranges with values ​​representing the upper and lower ends of the range, and such ranges are encompassed within the scope of the present disclosure.

[0029] Other embodiments will become apparent from review of the following detailed description. [Brief description of the drawings]

[0030] [Figure 1] 1 shows prophylactic dose-dependent tumor inhibition of BCMA-expressing NCI-H929 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459, respectively. NCI-H929 cells express high levels of BCMA. [Diagram 2] 1 shows prophylactic dose-dependent tumor inhibition of BCMA-expressing NCI-H929 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459, respectively. NCI-H929 cells express high levels of BCMA. [Diagram 3] 1 shows therapeutic dose-dependent tumor inhibition of established BCMA-expressing NCI-H929 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459, respectively. NCI-H929 cells express high levels of BCMA. [Figure 4] 1 shows therapeutic dose-dependent tumor inhibition of established BCMA-expressing NCI-H929 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459, respectively. NCI-H929 cells express high levels of BCMA. [Diagram 5]1 shows prophylactic dose-dependent tumor inhibition of BCMA-expressing MOLP-8 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459, respectively. MOLP-8 cells express moderate levels of BCMA. [Figure 6] 1 shows prophylactic dose-dependent tumor inhibition of BCMA-expressing MOLP-8 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459, respectively. MOLP-8 cells express moderate levels of BCMA. [Figure 7] Figure 2 shows therapeutic reduction of established tumor burden of BCMA-expressing OPM-2 human multiple myeloma tumor cells in vivo by anti-BCMA x anti-CD3 bispecific antibodies REGN5458 and REGN5459 compared to controls. OPM-2 cells express low levels of BCMA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] Before describing the present invention, it is to be understood that the present invention is not limited to the particular methods and experimental conditions described, as such methods and conditions may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, as the scope of the present invention is limited only by the appended claims.

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.As used herein, the term "about" means that when used in relation to a specific recited numerical value, the value may vary by 1% or less from the recited value.For example, as used in the present invention, the expression "about 100" includes 99 and 101, and all values ​​therebetween (for example, 99.1, 99.2, 99.3, 99.4, etc.).

[0033] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications, and non-patent publications mentioned herein are incorporated by reference in their entirety.

[0034] definition The term "CD3" as used herein refers to an antigen expressed on T cells as part of the multi-molecule T cell receptor (TCR) and consisting of a homodimer or heterodimer formed from the association of two of the four receptor chains, namely CD3-epsilon, CD3-delta, CD3-zeta, and CD3-gamma. Human CD3-epsilon comprises the amino acid sequence set forth in SEQ ID NO: 116, human CD3-delta comprises the amino acid sequence set forth in SEQ ID NO: 117, human CD3-zeta comprises the amino acid sequence set forth in SEQ ID NO: 118, and CD3-gamma comprises the amino acid sequence set forth in SEQ ID NO: 119. All references herein to proteins, polypeptides, and protein fragments are intended to refer to the human form of the respective protein, polypeptide, or protein fragment, unless expressly specified as being derived from a non-human species. Thus, the term "CD3" refers to human CD3, unless specified as being derived from a non-human species, e.g., "mouse CD3", "monkey CD3", etc.

[0035] As used herein, "antibodies that bind CD3" or "anti-CD3 antibodies" include antibodies and antigen-binding fragments thereof that specifically recognize a single CD3 subunit (e.g., epsilon, delta, gamma, or zeta), as well as antibodies and antigen-binding fragments thereof that specifically recognize a dimeric complex of two CD3 subunits (e.g., gamma / epsilon, delta / epsilon, and zeta / zeta CD3 dimers). The antibodies and antigen-binding fragments of the present invention can bind to soluble CD3 and / or cell surface expressed CD3. Soluble CD3 includes native CD3 protein as well as recombinant CD3 protein variants, such as, for example, monomeric and dimeric CD3 constructs, that lack a transmembrane domain or are not associated with a cell membrane.

[0036] As used herein, the phrase "cell surface expressed CD3" refers to one or more CD3 protein(s) expressed on the cell surface in vitro or in vivo, where at least a portion of the CD3 protein is exposed to the extracellular side of the cell membrane and is accessible to the antigen-binding portion of an antibody. "Cell surface expressed CD3" includes CD3 proteins contained within a functional T cell receptor within the cell membrane. The phrase "cell surface expressed CD3" refers to CD3 proteins expressed on the surface of a cell. The term "cell surface expressed CD3" includes CD3 proteins expressed as part of homodimers or heterodimers (e.g., gamma / epsilon, delta / epsilon, and zeta / zeta CD3 dimers). The term "cell surface expressed CD3" also includes CD3 chains expressed by themselves on the surface of a cell, without other CD3 chain types (e.g., CD3-epsilon, CD3-delta, or CD3-gamma). Alternatively, "cell surface expressed CD3" can include or consist of CD3 protein expressed on the surface of a cell that normally expresses CD3 protein. Alternatively, "cell surface expressed CD3" can include or consist of CD3 protein expressed on the surface of a cell that does not normally express human CD3 on its surface but has been artificially engineered to express CD3 on its surface.

[0037] The term "BCMA" as used herein refers to B cell maturation antigen.BCMA (also known as TNFRSF17 and CD269) is a cell surface protein expressed on malignant plasma cells and plays a central role in regulating B cell maturation and differentiation into immunoglobulin-producing plasma cells.The amino acid sequence of human BCMA is shown in SEQ ID NO: 115 and can also be found in GenBank accession number NP_001183.2.

[0038] As used herein, an "antibody that binds BCMA" or an "anti-BCMA antibody" includes antibodies and antigen-binding fragments thereof that specifically recognize BCMA.

[0039] The term "antigen-binding molecule" includes antibodies and antigen-binding fragments of antibodies, including, for example, bispecific antibodies.

[0040] As used herein, the term "antibody" refers to any antigen-binding molecule or molecular complex that contains at least one complementarity determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., BCMA or CD3). The term "antibody" includes immunoglobulin molecules that contain four polypeptide chains, two heavy (H) chains and two light (L) chains, interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). The term "antibody" also includes immunoglobulin molecules that contain four polypeptide chains, two heavy (H) chains and two light (L) chains, interconnected by disulfide bonds. Each heavy chain contains a heavy chain variable region (HCVR or VVR, as used herein). H The heavy chain constant region is made up of three domains: H 1. C H 2, and C H Each light chain comprises a light chain variable region (referred to herein as LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H Area and V LThe regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L consists of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of the anti-BCMA or anti-CD3 antibodies (or antigen-binding portions thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on the parallel analysis of two or more CDRs.

[0041] The term "antibody" as used herein also includes antigen-binding fragments of complete antibody molecules. "Antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody and similar terms as used herein include naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptides or glycoproteins that specifically bind antigens to form complexes. Antibody-binding fragments of antibodies can be derived from complete antibody molecules using any suitable standard techniques, such as, for example, proteolytic or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and, optionally, constant domains. Such DNA is known and may be used in a variety of applications. and / or may be readily available, e.g., from commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or may be synthesized. The DNA may be sequenced and manipulated, chemically or by using molecular biology techniques, e.g., to arrange one or more variable and / or constant domains into a suitable configuration, or to introduce codons, create cysteine ​​residues, modify, add or delete amino acids, etc.

[0042] Non-limiting examples of antibody-binding fragments include (i) Fab fragments, (ii) F(ab')2 fragments, (iii) Fd fragments, (iv) Fv fragments, (v) single-chain Fv (scFv) molecules, (vi) dAb fragments, and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions (e.g., isolated complementarity determining regions (CDRs), such as CDR3 peptides) of an antibody, or constrained FR3-CDR3-FR4 peptides. Domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains are also encompassed by the term "antigen-binding fragment" as used herein.

[0043] An antigen-binding fragment of an antibody will typically contain at least one variable domain. A variable domain may be of any size or amino acid composition and generally contains at least one CDR adjacent to or in frame with one or more framework sequences. L V bound to the domain H In an antibody-binding fragment having a domain, H Domains and V L The domains can be arranged relative to each other in any suitable configuration. For example, the variable region is a dimer and the V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may comprise a monomeric V H Domain or V L It may include a domain.

[0044] In certain embodiments, an antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody of the invention include: (i) a V H -C H 1, (ii) V H -C H 2. (iii) V H -C H 3. (iv) V H -C H 1-C H 2. (v) V H -C H 1-C H 2-C H 3. (vi) V H -C H 2-C H 3. (vii) V H -C L , (viii) V L -C H 1, (ix) V L -C H 2. (x)V L -C H 3. (xi) V L -C H 1-C H 2. (xii) V L -C H 1-C H 2-C H 3. (xiii) V L -C H 2-C H 3, and (xiv) V L -C LIn any configuration of the variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible connection between adjacent variable and / or constant domains in a single polypeptide molecule. Moreover, antigen-binding fragments of the antibodies of the present invention may be linked to each other and / or to one or more monomeric V H Domain or V L The domains may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in non-covalent association (e.g., by disulfide bond(s)).

[0045] As with intact antibody molecules, antibody binding fragments can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies will typically contain at least two different variable domains, each capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Examples disclosed herein include Any multispecific antibody format, including the exemplary bispecific antibody format, can be adapted for use in connection with antigen-binding fragments of the antibodies of the present invention using routine techniques available in the art.

[0046] The antibodies of the present invention may function through complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). "Complement-dependent cytotoxicity" (CDC) refers to the lysis of antigen-expressing cells by the antibodies of the present invention in the presence of complement. "Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a cell-mediated reaction in which non-specific cytotoxic cells expressing Fc receptors (FcRs) (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibodies on target cells, thereby resulting in the lysis of the target cells. CDC and ADCC can be measured using assays that are well known and available in the art. (See, e.g., U.S. Patent Nos. 5,500,362 and 5,821,337, and Clynes et al. (1998) Proc. Natl. Acad. Sci. (USA) 95:652-656). The constant region of an antibody is important in the ability of the antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, the isotype of the antibody can be selected based on whether it is desirable for the antibody to mediate cytotoxicity.

[0047] In certain embodiments, the anti-BCMA monospecific or anti-BCMA x anti-CD3 bispecific antibodies of the invention are human antibodies. The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies of the invention may include, for example, amino acid residues in the CDRs, particularly CDR3, that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or by in vivo somatic mutation). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been grafted onto human framework sequences.

[0048] The antibody of the present invention may, in some embodiments, be a recombinant human antibody. As used herein, the term "recombinant human antibody" is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described below), antibodies isolated from a recombinant combinatorial human antibody library (described below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies prepared, expressed, created or isolated by any other means, including splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, in the case of animals transgenic for human Ig sequences, in vivo somatic mutagenesis) to thereby modify the V and V regions of the recombinant antibody. H and V L The amino acid sequence of the region is H and V L These are sequences that, although derived and related to the sequences, may not naturally occur within the human antibody germline repertoire in vivo.

[0049] Human antibodies can exist in two forms related to hinge heterogeneity. In the first form, the immunoglobulin molecule comprises a stable four-chain construct of approximately 150-160 kDa in which the dimers are held together by interchain heavy chain disulfide bonds. In the second form, the dimers are not linked via interchain disulfide bonds, resulting in a molecule of approximately 75-80 kDa consisting of covalently linked light and heavy chains (half antibodies). These forms are distinct from the parent It has been shown to be extremely difficult to separate even after purification.

[0050] The frequency of occurrence of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody. A single amino acid substitution in the hinge region of a human IgG4 hinge can significantly reduce the occurrence of the second form to the level typically observed using a human IgG1 hinge (Angal et al. (1993) Molecular Immunology 30:105). The present invention provides a method for determining whether the second form occurs in the hinge, C H 2 or C H Antibodies with one or more mutations in three regions are included, which may be desirable, for example, in production to improve the yield of the desired antibody form.

[0051] The antibody of the present invention may be an isolated antibody. As used herein, "isolated antibody" refers to an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which it naturally occurs or is naturally produced, is an "isolated antibody" for the purposes of the present invention. An isolated antibody also includes an antibody in situ in a recombinant cell. An isolated antibody is an antibody that has been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0052] The present invention also includes one-arm antibodies that bind to BCMA. As used herein, "one-arm antibody" refers to an antigen-binding molecule that comprises a single antibody heavy chain and a single antibody light chain. The one-arm antibody of the present invention may comprise any of the HCVR / LCVR or CDR amino acid sequences set forth in Table 1.

[0053] The anti-BCMA or anti-BCMA x anti-CD3 antibodies disclosed herein may contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The present invention includes antibodies and antigen-binding fragments thereof derived from any of the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue(s) in the germline sequence from which the antibody was derived, or to the corresponding residue(s) in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one of skill in the art can readily produce many antibodies and antibody-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, the V H and / or V LAll framework and / or CDR residues within the domain are mutated back to the residue found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., the mutated residue is found within the first 8 amino acids of FR1, or the mutated residue is found within the last 8 amino acids of FR4, or the mutated residue is found only in CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and / or CDR residue(s) are mutated to the corresponding residue(s) in a different germline sequence (i.e., a germline sequence different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations within the framework and / or CDR regions, e.g., certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residue in a different germline sequence. Once obtained, antibodies and antibodies containing one or more germline mutations can be used. Binding fragments can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonist or agonist biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antibody binding fragments obtained in this general manner are encompassed within the scope of the present invention.

[0054] The invention also includes anti-BCMA or anti-BCMAx anti-CD3 antibodies comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the invention includes anti-BCMA or anti-BCMAx anti-CD3 antibodies having HCVR, LCVR, and / or CDR amino acid sequences with, for example, 10 or less, 8 or less, 6 or less, or 4 or less conservative amino acid substitutions relative to any of the HCVR, LCVR, and / or CDR amino acid sequences set forth in Tables 1 and 3 herein, or anti-CD3 antibodies disclosed in WO2014 / 047231 or WO2017 / 053856 (each of which is incorporated herein by reference).

[0055] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule, known as the paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different regions on an antigen and have different biological effects. Epitopes can be either conformational or linear. Conformational epitopes are generated by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. Linear epitopes are those generated by adjacent amino acid residues in a polypeptide chain. In certain circumstances, epitopes can include carbohydrate, phosphoryl, or sulfonyl moieties on an antigen.

[0056] The term "substantial identity" or "substantially identical," when referring to a nucleic acid or a fragment thereof, indicates that when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is at least about 95%, more preferably at least about 96%, 97%, 98%, or 99% nucleotide sequence identity of the nucleotide bases as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST, or Gap, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule can, in certain cases, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0057] As applied to polypeptides, the term "substantial similarity" or "substantially similar" refers to two peptide sequences that share at least 95% sequence identity, and even more preferably at least 98% or 99% sequence identity, when optimally aligned, such as by the programs GAP or BESTFIT, using predefined gap weights. Preferably, residue positions that are not identical differ only by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions are not expected to substantially alter the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percentage of sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24:307-331, incorporated herein by reference. Examples of groups of amino acids having side chains with similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; and (5) Basic side chains include lysine, arginine, and histidine, (6) acidic side chains aspartic acid and glutamic acid, and (7) sulfur-containing side chains cysteine ​​and methionine.Preferred conservative amino acid substitutions are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine.Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443-1445, which is incorporated herein by reference.A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0058] Sequence similarity for polypeptides, also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software uses similarity measurements assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions, to match similar sequences. For example, GCG software contains programs such as Gap and Bestfit, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms, or between a wild-type protein and its mutant protein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and percent sequence identity of the region of best overlap between the query sequence and the search sequence (Pearson (2000) supra). Another preferred algorithm for comparing the sequences of the present invention to a database containing a large number of sequences from different organisms is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402, each of which is incorporated herein by reference.

[0059] Germline mutations The anti-CD3 antibodies disclosed herein contain one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy chain variable domain compared to the corresponding germline sequences.

[0060] The present invention also includes antibodies and antigen-binding fragments thereof derived from any of the amino acid sequences disclosed herein, where one or more amino acids in one or more framework and / or CDR regions have been mutated to the corresponding residue(s) in the germline sequence from which the antibody was derived, or to the corresponding residue(s) in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes collectively referred to herein as "germline mutations") and have weak or no detectable binding to the CD3 antigen.

[0061] Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations in the framework and / or CDR regions, for example, certain individual residues are mutated to the corresponding residues of a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residues of a different germline sequence. Once obtained, antibodies and antibody-binding fragments containing one or more germline mutations can be tested for one or more desired properties, such as improved binding specificity, weak or reduced binding affinity, improved or enhanced pharmacokinetic properties, reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner, taking into account the guidance of the present disclosure, are encompassed within the scope of the present invention.

[0062] The present invention also includes antigen-binding molecules that include an antigen-binding domain having an HCVR and / or CDR amino acid sequence that is substantially identical to any of the HCVR and / or CDR amino acid sequences disclosed herein, but maintain or improve the desired weak affinity to the CD3 antigen. When referring to amino acid sequences, the term "substantial identity" or "substantially identical" means that two amino acid sequences share at least 95% sequence identity, even more preferably at least 98%, or 99% sequence identity, when optimally aligned, such as by the programs GAP or BESTFIT, using predefined gap weights. Preferably, residue positions that are not identical differ only by conservative amino acid substitutions. When two or more amino acid sequences differ from each other only by conservative substitutions, the percentage of sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24:307-331.

[0063] Sequence similarity for polypeptides, also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software uses similarity measurements assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions, to match similar sequences. For example, GCG software contains programs such as Gap and Bestfit, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms, or between a wild-type protein and its mutant protein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and percent sequence identity of the region of best overlap between the query sequence and the search sequence (Pearson (2000) supra). Another preferred algorithm for comparing the sequences of the present invention to a database containing a large number of sequences from different organisms is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402.

[0064] Antibody Binding Properties As used herein, the term "binding" in the context of the binding of either an antibody, immunoglobulin, antibody binding fragment, or Fc-containing protein to a given antigen, such as, for example, a cell surface protein or fragment thereof, typically refers to an interaction or association between at least two entities or molecular structures, such as an antibody-antigen interaction.

[0065] For example, binding affinities are typically around 10 when determined by surface plasmon resonance (SPR) techniques, e.g., on a BIAcore 3000 instrument, using an antigen as the ligand and an antibody, Ig, antibody binding fragment, or Fc-containing protein as the analyte (or antiligand). -7 M or less, for example, about 10 -8 M or less, for example, about 10 -9 K below M D Cell-based binding strategies such as fluorescence-activated cell sorting (FACS) binding assays are also routinely used, and FACS data correlate well with other methods such as radioligand competitive binding and SPR (Benedict, CA, J Immunol Methods. 1997, 201(2):223-31; Geuijen, CA, et al. J Immunol Methods. 2005, 302(1-2):68-77).

[0066] Thus, the antibodies or antigen binding proteins of the invention can be used to bind non-specific antigens (e.g., BSA, Its affinity for binding to α-casein is at least 10 times lower than its K D According to the present invention, the antibody binds to a given antigen or cell surface molecule with an affinity corresponding to a K value that is 10-fold lower than that of a non-specific antigen. D Although an antibody affinity corresponding to the value may be considered as undetectable binding, such an antibody may be paired with a second antigen-binding arm to produce a bispecific antibody of the invention.

[0067] "K D The term "M" refers to the dissociation equilibrium constant of a particular antibody-antigen interaction or the dissociation equilibrium constant of an antibody or antibody-binding fragment that binds to an antigen. D There is an inverse relationship between the binding affinity and the K D The smaller the value, the higher, i.e., the stronger, the affinity. Thus, the terms "higher affinity" or "stronger affinity" refer to a higher ability to form an interaction, i.e., a smaller K DConversely, the term "lower affinity" or "weaker affinity" refers to a lower ability to form an interaction, i.e., a larger K D In some situations, the higher binding affinity (or K) of a particular molecule (e.g., an antibody) to an interaction partner molecule (e.g., antigen X) compared to the binding affinity of the molecule (e.g., an antibody) to another interaction partner molecule (e.g., antigen Y) can be used to refer to a higher binding affinity (or K D ) is larger than K D The smaller the K value (lower, or weaker, affinity), the D (higher, or stronger, affinity), e.g., 5-fold or 10-fold higher binding affinity, as the case may be.

[0068] "k d The term "(sec-1 or 1 / s)" refers to the dissociation rate constant of a particular antibody-antigen interaction, or the dissociation rate constant of an antibody or antibody-binding fragment. Its value is k off Also called value.

[0069] "k a The term "(M-1 x sec-1 or 1 / M) refers to the association rate constant of a particular antibody-antigen interaction, or the association rate constant of an antibody or antibody binding fragment.

[0070] "K A The term "(M-1 or 1 / M)" refers to the association equilibrium constant of a particular antibody-antigen interaction, or the association equilibrium constant of an antibody or antibody binding fragment. The association equilibrium constant is k a k d It is obtained by dividing by.

[0071] "EC50" or "EC 50 The term "half maximal effective concentration" refers to the concentration of an antibody that induces a response halfway between the baseline and maximum after a particular exposure time. EC 50 essentially represents the concentration of an antibody at which 50% of its maximal effect is observed. In certain embodiments, the EC 50The EC value is equal to the concentration of an antibody of the invention that confers half-maximal binding to cells expressing CD3 or a tumor-associated antigen (e.g., BCMA) as determined, for example, by a FACS binding assay. Thus, reduced or weak binding is an EC 50 An increase in the concentration of 100 mg / kg / day or half-maximal effective concentration values ​​is observed.

[0072] In one embodiment, the reduction in binding is an EC2 concentration that allows half-maximal binding to target cells. 50 It can be defined as an increase in antibody concentration.

[0073] In another embodiment, EC 50 The values ​​represent the concentration of the antibody of the invention that induces half-maximal depletion of target cells by the cytotoxic activity of T cells. Thus, an increase in cytotoxic activity (e.g., T cell-mediated tumor cell killing) is associated with an EC 50 A decrease in the concentration of 100 mg / kg / day or half the maximum effective concentration value is observed.

[0074] Bispecific antigen binding molecules The antibodies of the present invention may be monospecific, bispecific or multispecific. Multispecific antibodies may be specific for different epitopes of one target polypeptide or may contain antigen binding domains specific for two or more target polypeptides. For example, Tutte et al. See, e.g., Kufer et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244. The anti-BCMA monospecific or anti-BCMA x anti-CD3 bispecific antibodies of the invention can be linked to or co-expressed with another functional molecule, e.g., another peptide or protein. For example, an antibody or fragment thereof can be functionally linked (e.g., by chemical conjugation, genetic fusion, non-covalent association, etc.) to one or more other molecular entities, such as another antibody or antibody fragment, to generate a bispecific or multispecific antibody having a second or additional binding specificity.

[0075] The use of the phrase "anti-CD3 antibody" or "anti-BCMA antibody" herein is intended to include both monospecific anti-CD3 or anti-BCMA antibodies, as well as bispecific antibodies comprising a CD3-binding arm and a BCMA-binding arm. Thus, the present invention includes bispecific antibodies in which one arm of the immunoglobulin binds human CD3 and the other arm of the immunoglobulin is specific for human BCMA. The CD3-binding arm may comprise any of the HCVR / LCVR or CDR amino acid sequences set out in Table 3 herein, or the anti-CD3 antibodies disclosed in WO2014 / 047231 or WO2017 / 053856.

[0076] In certain embodiments, the CD3 binding arm binds to human CD3 and induces human T cell activation. In certain embodiments, the CD3 binding arm binds weakly to human CD3 and induces human T cell activation. In other embodiments, the CD3 binding arm binds weakly to human CD3 and induces tumor-associated antigen-expressing cell killing in the context of a bispecific or multispecific antibody. In other embodiments, the CD3 binding arm binds or associates weakly with human and cynomolgus (monkey) CD3, yet the binding interaction is not detectable by in vitro assays known in the art. The BCMA binding arm may comprise any of the HCVR / LCVR or CDR amino acid sequences listed in Table 1 herein.

[0077] According to certain exemplary embodiments, the present invention includes bispecific antigen binding molecules that specifically bind to CD3 and BCMA. Such molecules may be referred to herein as, for example, "anti-BCMA x anti-CD3" or "anti-CD3 / anti-BCMA", or "anti-CD3 x BCMA" or "CD3 x BCMA" bispecific molecules, or other similar terms (e.g., anti-BCMA / anti-CD3).

[0078] As used herein, the term "BCMA" refers to the human BCMA protein, unless specified as being derived from a non-human species (e.g., "mouse BCMA", "monkey BCMA", etc.). The human BCMA protein has the amino acid sequence set forth in SEQ ID NO:115.

[0079] The bispecific antigen-binding molecules that specifically bind to CD3 and BCMA have a K of greater than about 40 nM as measured in an in vitro affinity binding assay. D The anti-CD3 antigen binding molecule may include an anti-CD3 antigen binding molecule that binds to CD3 with a weak binding affinity exhibiting a

[0080] As used herein, the term "antigen-binding molecule" refers to a protein, polypeptide, or molecular complex comprising or consisting of at least one complementarity determining region (CDR) alone or in combination with one or more additional CDRs and / or framework regions (FRs) that specifically binds to a particular antigen. In certain embodiments, the antigen-binding molecule is an antibody or an antibody fragment, as those terms are defined elsewhere herein.

[0081] As used herein, the term "bispecific antigen-binding molecule" refers to a bispecific antigen-binding molecule comprising at least one Bispecific antigen-binding domain refers to a protein, polypeptide, or molecular complex that comprises one antigen-binding domain and a second antigen-binding domain. Each antigen-binding domain in a bispecific antigen-binding molecule comprises at least one CDR that specifically binds to a particular antigen, either alone or in combination with one or more additional CDRs and / or FRs. In the context of the present invention, the first antigen-binding domain specifically binds to a first antigen (e.g., BCMA), and the second antigen-binding domain specifically binds to a second, different antigen (e.g., CD3).

[0082] In certain exemplary embodiments of the present invention, the bispecific antigen-binding molecule is a bispecific antibody. Each antigen-binding domain of the bispecific antibody comprises a heavy chain variable domain (HCVR) and a light chain variable domain (LCVR). In the context of a bispecific antigen-binding molecule (e.g., a bispecific antibody) comprising a first and a second antigen-binding domain, the CDR of the first antigen-binding domain may be designated with the prefix "D1", and the CDR of the second antigen-binding domain may be designated with the prefix "D2". Thus, the CDR of the first antigen-binding domain may be referred to herein as D1-HCDR1, D1-HCDR2, and D1-HCDR3, and the CDR of the second antigen-binding domain may be referred to herein as D2-HCDR1, D2-HCDR2, and D2-HCDR3.

[0083] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule comprises a first antigen-binding domain comprising (a) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) comprised within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 66, and (b) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) comprised within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 82. In some cases, the isolated bispecific antigen-binding molecule comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 68, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 70, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 72. In some cases, the isolated bispecific antigen-binding molecule comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 84, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 86, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 88. In some cases, the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:66 and a LCVR comprising the amino acid sequence of SEQ ID NO:82.

[0084] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule comprises a second antigen-binding domain comprising (a) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) comprised within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 90 or SEQ ID NO: 98, and (b) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) comprised within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 82. In some cases, the second antigen-binding domain comprises (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 100, (b) an HCDR2 comprising the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 102, and (c) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 96 or SEQ ID NO: 104. In some cases, the second antigen-binding domain comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 84, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 86, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 88. In some cases, the second antigen-binding domain comprises (a) an HCDR1, HCDR2, HCDR3 domain comprising the amino acid sequence of SEQ ID NO: 92, 94, 96, respectively, and an LCDR1, LCDR2, LCDR3 domain comprising the amino acid sequence of SEQ ID NO: 84, 86, 88, respectively, or (b) an HCDR1, HCDR2, HCDR3 domain comprising the amino acid sequence of SEQ ID NO: 100, 102, 104, respectively, and an LCDR1, LCDR2, LCDR3 domain comprising the amino acid sequence of SEQ ID NO: 84, 86, 88, respectively. In some cases, the second antigen-binding domain comprises (a) an HCVR comprising the amino acid sequence of SEQ ID NO: 90, and an LCVR comprising the amino acid sequence of SEQ ID NO: 82, or (b) an HCVR comprising the amino acid sequence of SEQ ID NO: 98, and an LCVR comprising the amino acid sequence of SEQ ID NO: 82.

[0085] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 68, 70, 72, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively; and (b) a second antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 92, 94, 96, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively. In some cases, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 66 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82; and (b) a second antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 90 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82.

[0086] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 68, 70, 72, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively; and (b) a second antigen-binding domain comprising HCDR1, HCDR2, HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 100, 102, 104, respectively, and LCDR1, LCDR2, LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, 88, respectively. In some cases, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 66 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82; and (b) a second antigen-binding domain comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 98 and an LCVR comprising the amino acid sequence of SEQ ID NO: 82.

[0087] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule comprises (a) a first antigen-binding domain that specifically binds human BCMA and comprises a CDR of an HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 122, and 124, and a CDR of an LCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 82, 123, and 125, and (b) a second antigen-binding domain that specifically binds human CD3. In some cases, the first antigen-binding domain comprises the CDRs from a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 122 / 123, 124 / 125, 2 / 82, 18 / 82, 34 / 82, 50 / 82, 66 / 82, 122 / 82, and 124 / 82. In some cases, the first antigen binding domain comprises a HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domain selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, 20-22-24-28-30-32, 36-38-40-44-46-48, 52-54-56-60-62-64, 68-70-72-76-78-80, 4-6-8-84-86-88, 20-22-24-84-86-88, 36-38-40-84-86-88, 52-54-56-84-86-88, and 68-70-72-84-86-88, respectively. In some cases, the first antigen-binding domain comprises a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 122 / 123, 124 / 125, 2 / 82, 18 / 82, 34 / 82, 50 / 82, 66 / 82, 122 / 82, and 124 / 82. In some cases, the second antigen-binding domain comprises the CDRs of a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 90 / 82 and 98 / 82.

[0088] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule is A, or binds to the same epitope on BCMA as a reference antibody, the reference antibody comprising a first antigen-binding domain comprising an HCVR / LCVR pair comprising the amino acid sequence of SEQ ID NO:66 / 82, and a second antigen-binding domain comprising an HCVR / LCVR pair comprising the amino acid sequence of either SEQ ID NO:90 / 82 or SEQ ID NO:98 / 82.

[0089] In certain exemplary embodiments, the isolated bispecific antigen-binding molecule competes for binding to human CD3 or binds to the same epitope on human CD3 as a reference antibody, the reference antibody comprising a first antigen-binding domain comprising an HCVR / LCVR pair comprising the amino acid sequence of SEQ ID NO:66 / 82 and a second antigen-binding domain comprising an HCVR / LCVR pair comprising the amino acid sequence of either SEQ ID NO:90 / 82 or SEQ ID NO:98 / 82.

[0090] The bispecific antigen-binding molecule described above or herein can be a bispecific antibody. In some cases, the bispecific antibody comprises a human IgG heavy chain constant region. In some cases, the human IgG heavy chain constant region is of isotype IgG1. In some cases, the human IgG heavy chain constant region is of isotype IgG4. In various embodiments, the bispecific antibody comprises a chimeric hinge that reduces Fcγ receptor binding compared to a wild-type hinge of the same isotype.

[0091] The first antigen-binding domain and the second antigen-binding domain may be directly or indirectly linked to each other to form the bispecific antigen-binding molecule of the present invention. Alternatively, the first antigen-binding domain and the second antigen-binding domain may each be linked to a separate multimerization domain. The association of one multimerization domain with another multimerization domain promotes the association between the two antigen-binding domains, thereby forming a bispecific antigen-binding molecule. As used herein, a "multimerization domain" is any macromolecule, protein, polypeptide, peptide, or amino acid that has the ability to associate with a second multimerization domain of the same or similar structure or composition. For example, a multimerization domain may be linked to the immunoglobulin CH A non-limiting example of a multimerizing component is the Fc portion of an immunoglobulin (C H 2-C H 3 domains), such as the Fc domain of IgG selected from the isotypes IgG1, IgG2, IgG3, and IgG4, as well as allotypes within each isotype group.

[0092] The bispecific antigen-binding molecules of the present invention typically comprise two multimerization domains, e.g., two Fc domains, each part of a separate antibody heavy chain. The first and second multimerization domains may be of the same IgG isotype, e.g., IgG1 / IgG1, IgG2 / IgG2, IgG4 / IgG4, etc. Alternatively, the first and second multimerization domains may be of different IgG isotypes, e.g., IgG1 / IgG2, IgG1 / IgG4, IgG2 / IgG4, etc.

[0093] In certain embodiments, the multimerization domain is an Fc fragment or an amino acid sequence of 1 to about 200 amino acids in length containing at least one cysteine ​​residue. In other embodiments, the multimerization domain is a cysteine ​​residue, or a short cysteine-containing peptide. Other multimerization domains include peptides or polypeptides that include or consist of leucine zipper, helix-loop-helix, or coiled-coil motifs.

[0094] Any bispecific antibody format or technology can be used to generate the bispecific antigen-binding molecules of the present invention. For example, an antibody or fragment thereof having a first antigen-binding specificity can be functionally linked (e.g., by chemical bonding, genetic fusion, non-covalent bonding, etc.) to one or more other molecular entities, such as other antibodies or antibody fragments having a second antigen-binding specificity, to generate bispecific antigen-binding molecules. Specific bispecific antibody formats or technologies that can be used in the context of the present invention include, but are not limited to, those described herein. Exemplary bispecific formats include, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab 2 These include, but are not limited to, bispecific formats (for a review of the aforementioned formats, see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and references cited therein).

[0095] In the context of the bispecific antigen-binding molecules of the present invention, the multimerization domain, e.g., the Fc domain, may contain one or more amino acid changes (e.g., insertions, deletions, or substitutions) compared to a wild-type, naturally occurring Fc domain. For example, the present invention includes bispecific antigen-binding molecules that contain one or more modifications in the Fc domain that result in an altered Fc domain with modified binding interactions (e.g., enhanced or decreased) between Fc and FcRn. In one embodiment, the bispecific antigen-binding molecule comprises a C H 2 or C HThe FcRn-containing FcRn-binding domain contains modifications in three regions that increase the affinity of the Fc domain for FcRn in an acidic environment (e.g., in an endosome at a pH range of about 5.5 to about 6.0). Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q), 250 and 428 (e.g., L or F), 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T), or modifications at positions 428 and / or 433 (e.g., L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y), or modifications at positions 250 and / or 428, or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications include the 428L (e.g., M428L) and 434S (e.g., N434S) modifications, the 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications, the 433K (e.g., H433K) and 434 (e.g., 434Y) modifications, the 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications, the 250Q and 428L modifications (e.g., T250Q and M428L), the 307 and / or 308 modifications (e.g., 308F or 308P).

[0096] The present invention also relates to a first C H 3 domain and second IgC H The present invention relates to a bispecific antigen-binding molecule comprising a first and a second IgC H The three domains differ from each other by at least one amino acid, and the at least one amino acid difference reduces binding of the bispecific antibody to Protein A compared to a bispecific antibody lacking the amino acid difference. H The 3 domain binds protein A and is a second IgC H The C3 domain contains a mutation that reduces or abolishes Protein A binding, such as the H95R modification (according to IMGT exon numbering, H435R in EU numbering). H3 may further include a Y96F modification (IMGT, Y436F in EU). See, e.g., U.S. Patent No. 8,586,713. H Further modifications that may be found within 3 include for IgG1 antibodies, D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT and D356E, L358M, N384S, K392N, V397M, and V422I by EU), for IgG2 antibodies, N44S, K52N, and V82I (by IMGT and N384S, K392N, and V422I by EU), and for IgG4 antibodies, Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT and Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU).

[0097] In certain embodiments, the Fc domain can be a chimera that combines Fc sequences from two or more immunoglobulin isotypes. For example, a chimeric Fc domain can be a chimera that combines Fc sequences from human IgG1, human IgG2, or human IgG4. H C derived from 2 regions H 2 sequences, and C derived from human IgG1, human IgG2, or human IgG4. H The chimeric Fc domain may comprise some or all of the three sequences. The chimeric Fc domain may also comprise a chimeric hinge region. For example, the chimeric hinge may comprise an "upper hinge" sequence derived from a human IgG1 hinge region, a human IgG2 hinge region, or a human IgG4 hinge region, combined with a "lower hinge" sequence derived from a human IgG1 hinge region, a human IgG2 hinge region, or a human IgG4 hinge region. A specific example of a chimeric Fc domain that may be included in any of the antigen-binding molecules described herein is a chimeric Fc domain that comprises, from the N-terminus to the C-terminus, a chimeric Fc domain comprising the sequences: [IgG4C H Another example of a chimeric Fc domain that may be included in any of the antigen-binding molecules described herein comprises, from the N-terminus to the C-terminus, [IgG1C H1]-[IgG1 upper hinge]-[IgG2 lower hinge]-[IgG4 CH2]-[IgG1 CH3]. These and other examples of chimeric Fc domains that may be included in any of the antigen-binding molecules of the invention are described in U.S. Patent Publication No. 2014 / 0243504, published August 28, 2014, and incorporated herein in its entirety. Chimeric Fc domains having these general structural arrangements, and variants thereof, can alter Fc receptor binding, which in turn affects Fc effector function.

[0098] Sequence variants The antibodies and bispecific antigen-binding molecules herein may contain one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences from which the individual antigen-binding domains were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The antigen-binding molecules of the present invention may contain antigen-binding domains derived from any of the exemplary amino acid sequences disclosed herein, where one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue(s) in the germline sequence from which the antibody was derived, or to the corresponding residue(s) in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one skilled in the art can readily produce numerous antibodies and antibody-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, the V H Domain and / or V LAll framework and / or CDR residues within the domain are mutated back to the residue found in the original germline sequence from which the antigen-binding domain was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., the mutated residue is found within the first 8 amino acids of FR1, or the mutated residue is found within the last 8 amino acids of FR4, or the mutated residue is found only in CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and / or CDR residue(s) are mutated to the corresponding residue(s) in a different germline sequence (i.e., a germline sequence that differs from the germline sequence from which the antigen-binding domain was originally derived). Furthermore, the antigen-binding domain may contain any combination of two or more germline mutations within the framework and / or CDR regions, e.g., certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residue in a different germline sequence. Once obtained, antigen-binding domains containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonist or agonist biological properties (as the case may be), reduced immunogenicity, etc. Bispecific antigen-binding molecules comprising one or more antigen-binding domains are encompassed within the scope of the present invention.

[0099] pH dependent binding The present invention includes anti-BCMA antibodies and anti-BCMA x anti-CD3 bispecific antigen binding molecules with pH-dependent binding properties. For example, the anti-BCMA antibodies of the present invention may exhibit reduced binding to BCMA at acidic pH compared to neutral pH. Alternatively, the anti-BCMA antibodies of the present invention may exhibit enhanced binding to BCMA at acidic pH compared to neutral pH. The term "acidic pH" includes pH values ​​below about 6.2, such as about 6.0, 5.95, 5, 9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0 or less. As used herein, the term "neutral pH" refers to a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values ​​of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.

[0100] In some cases, "decreased binding ... at acidic pH compared to neutral pH" refers to the K of an antibody that binds to its antigen at neutral pH. D K value for an antibody that binds to its antigen at acidic pH D For example, an antibody or antigen-binding fragment thereof may have an acidic / neutral K of about 3.0 or greater. D When a ratio is presented, for purposes of the present invention, an antibody or antigen-binding fragment thereof may be considered to exhibit "reduced binding to BCMA at acidic pH compared to neutral pH." In certain exemplary embodiments, the acidic / neutral K of an antibody or antigen binding of the present invention may be expressed as: D The ratio can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0, or more.

[0101] Antibodies with pH-dependent binding properties can be obtained, for example, by screening a population of antibodies for reduced (or enhanced) binding to a particular antigen at acidic pH compared to neutral pH. Furthermore, modification of the antigen-binding domain at the amino acid level can produce antibodies with pH-dependent characteristics. For example, by replacing one or more amino acids in the antigen-binding domain (e.g., in the CDRs) with histidine residues, an antibody can be obtained that has reduced antigen binding at acidic pH versus neutral pH.

[0102] Antibodies Containing Fc Variants According to certain embodiments of the invention, anti-BCMA antibodies and anti-BCMA x anti-CD3 bispecific antigen binding molecules are provided that comprise an Fc domain that contains one or more mutations that enhance or decrease antibody binding to the FcRn receptor at, for example, acidic pH compared to neutral pH. H 2 or C H Antibodies containing mutations in the 3 region, where the mutation(s) increase the affinity of the Fc domain for FcRn in acidic environments (e.g., in endosomes where the pH ranges from about 5.5 to about 6.0). Such mutations can result in increased serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q), 250 and 428 (e.g., L or F), 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T), or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y), or modifications at positions 250 and / or 428, or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications are 428L (e.g., M428L) and 434S (e.g., N434S), 428 Modifications include the L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications, the 433K (e.g., H433K) and 434 (e.g., 434Y) modifications, the 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications, the 250Q and 428L modifications (e.g., T250Q and M428L), the 307 and / or 308 modifications (e.g., 308F or 308P).

[0103] For example, the invention includes anti-BCMA antibodies, and anti-BCMA x anti-CD3 bispecific antigen binding molecules, comprising an Fc domain that comprises one or more pairs or groups of mutations selected from the group consisting of 250Q and 248L (e.g. T250Q and M248L), 252Y, 254T and 256E (e.g. M252Y, S254T and T256E), 428L and 434S (e.g. M428L and N434S), and 433K and 434F (e.g. H433K and N434F). All possible combinations of the aforementioned Fc domain mutations, and other mutations in the antibody variable domains disclosed herein, are contemplated within the scope of the present invention.

[0104] Biological properties of antibodies and bispecific antigen-binding molecules The present invention provides antibodies that have high affinity (e.g., subnanomolar K D The present invention includes antibodies and antigen-binding fragments thereof that bind to human BCMA having an antibody binding domain (Ab) and an antibody binding domain (Bc) that binds to human BCMA and has an antibody binding domain (Bc ...

[0105] According to certain embodiments, the present invention provides a method for the preparation of a medicament for the treatment of cancer, comprising administering to the patient a medicament for the treatment of cancer, the method ... DIn certain embodiments, the antibodies or antigen-binding fragments of the invention have a K of less than about 20 nM, less than about 10 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 800 pM, less than about 700 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 50 pM, or less than about 25 pM when measured using surface plasmon resonance, e.g., an assay format as defined in Example 4 herein, or a substantially similar assay. D The present invention relates to bispecific antigen-binding molecules (e.g., having a K of less than about 25 pM when measured using surface plasmon resonance, e.g., an assay format as defined in Example 4 herein, or in a substantially similar assay). D and binds to human BCMA having a K of less than about 170 pM. D The present invention includes a bispecific antibody that binds to monkey BCMA having the following structure:

[0106] The invention also includes antibodies and antigen-binding fragments thereof that bind to BCMA with a dissociation half-life (t1 / 2) of greater than about 10 minutes or greater than about 125 minutes, when measured by surface plasmon resonance at 25° C., e.g., using an assay format defined in Example 4 herein, or in a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments of the invention bind to BCMA with a t1 / 2 of greater than about 3 minutes, greater than about 4 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than about 80 minutes, greater than about 90 minutes, greater than about 100 minutes, greater than about 110 minutes, or greater than about 120 minutes, when measured by surface plasmon resonance at 25° C., e.g., using an assay format defined in Example 4 herein, or in a substantially similar assay. The present invention includes bispecific antigen binding molecules (e.g. bispecific antibodies that bind to BCMA in greater than about 10 minutes as measured by surface plasmon resonance at 25°C, e.g. using an assay format defined in Example 4 herein, or in a substantially similar assay.

[0107] The present invention also provides antibodies that specifically bind to human cell lines expressing endogenous BCMA (e.g., NCI-H929, MOLP-8, or OMP-2) as determined by the FACS binding assay described in Example 6 or a substantially similar assay, and their antigen binding. Fragments are also included.

[0108] The present invention also includes anti-BCMA x anti-CD3 bispecific antigen binding molecules that exhibit one or more characteristics selected from the group consisting of: (a) inhibiting tumor growth in immunodeficient mice bearing human multiple myeloma xenografts; (b) suppressing tumor growth of established tumors in immunodeficient mice bearing human multiple myeloma xenografts (see, e.g., Examples 10-15); and (c) suppressing tumor growth of syngenic melanoma and colon cancer cells engineered to express human BCMA in immunocompetent mice expressing human CD3.

[0109] The present invention includes antibodies and antigen-binding fragments thereof that bind to human CD3 with high affinity. The present invention also includes antibodies and antigen-binding fragments thereof that bind to human CD3 with moderate or low affinity, depending on the therapeutic context and the particular targeting properties desired. In some cases, low affinity includes a K of greater than 300 nM, greater than 500 nM, or greater than 1 μM. D or EC 50 The present invention also includes antibodies and antigen-binding fragments thereof that bind to human CD3 with undetectable affinity (e.g., as measured by surface plasmon resonance assay). For example, in the context of a bispecific antigen-binding molecule in which one arm binds to CD3 and another arm binds to a target antigen (e.g., BCMA), it is desirable for the target antigen-binding arm to bind to the target antigen with high affinity, while the anti-CD3 arm binds to CD3 with moderate or low affinity or no affinity. In this manner, preferential targeting of the antigen-binding molecule to cells expressing the target antigen can be achieved while avoiding general / non-targeted CD3 binding and the resulting adverse side effects associated therewith.

[0110] The present invention includes bispecific antigen-binding molecules (e.g., bispecific antibodies) that can simultaneously bind to human CD3 and human BCMA. The binding arms that interact with cells expressing CD3 may have weak to undetectable binding as measured in a suitable in vitro binding assay. The extent to which a bispecific antigen-binding molecule binds to cells expressing CD3 and / or BCMA can be assessed by fluorescence-activated cell sorting (FACS), as shown in Examples 5 and 6 herein.

[0111] For example, the present invention includes antibodies, antibody binding fragments, and bispecific antibodies thereof that specifically bind to human cell lines that express CD3, but do not express BCMA (e.g., Jurkat) and / or BCMA expressing cells.

[0112] The present invention includes antibodies, antibody-binding fragments thereof, and bispecific antibodies thereof that bind to human CD3 with weak (ie, low) or even undetectable affinity.

[0113] The present invention includes antibodies, antibody-binding fragments thereof, and bispecific antibodies thereof that bind to monkey (ie, cynomolgus) CD3 with weak (ie, low) or even undetectable affinity.

[0114] The present invention includes antibodies, antigen-binding fragments thereof, and bispecific antibodies thereof that bind to human CD3 and induce T cell activation.

[0115] The present invention includes anti-BCMA x anti-CD3 bispecific antigen binding molecules capable of depleting or reducing tumor antigen expressing cells in a subject (see, e.g., Examples 8-16, or substantially similar assays). For example, according to certain embodiments, anti-BCMA x anti-CD3 bispecific antigen binding molecules are provided, and a single or multiple administration of 0.04 mg / kg, 0.4 mg / kg, or 4 mg / kg of the bispecific antigen binding molecule to a subject is causing a reduction in the number of BCMA-expressing cells in the subject (e.g., tumor growth in the subject is suppressed or inhibited).

[0116] Epitope mapping and related techniques The epitope on CD3 and / or BCMA to which the antigen binding molecule of the present invention binds may consist of a single contiguous sequence of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) amino acids of the CD3 or BCMA protein. Alternatively, the epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) of CD3 or BCMA. The antibodies of the present invention may interact with amino acids contained within a single CD3 chain (e.g., CD3-epsilon, CD3-delta, or CD3-gamma) or with amino acids on two or more different CD3 chains. As used herein, the term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of the antibody molecule known as the paratope. A single antigen may have two or more epitopes. Thus, different antibodies may bind to different regions on an antigen and have different biological effects. Epitopes can be either conformational or linear. Conformational epitopes are generated by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. Linear epitopes are generated by adjacent amino acid residues in a polypeptide chain. In certain circumstances, epitopes can include carbohydrate, phosphoryl, or sulfonyl moieties on an antigen.

[0117] Various techniques known to those skilled in the art can be used to determine whether the antigen-binding domain of an antibody "interacts with one or more amino acids" in a polypeptide or protein. Exemplary techniques include routine cross-blocking assays, as described, for example, in Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY), alanine scanning mutation analysis, peptide blot analysis (Reineke, 2004, Methods Mol Biol 248:443-463), and peptide truncation analysis. In addition, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be employed (Tomer (2000) Protein Science 9:487-496). Another method that can be used to identify the amino acids in a polypeptide that the antigen-binding domain of an antibody interacts with is hydrogen / deuterium exchange, detected by mass spectrometry. Generally speaking, hydrogen / deuterium exchange involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. The protein / antibody complex is then transferred to water to allow hydrogen-deuterium exchange to occur at all residues except those protected by the antibody (which remain deuterium-labeled). After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry, thereby revealing the deuterium-labeled residues that correspond to the specific amino acids with which the antibody interacts. See, for example, Ehring (1999) Analytical Biochemistry 267(2):252-259; Engen and Smith (2001) Anal.Chem.73:256A-265A. X-ray crystallography of antigen / antibody complexes may also be used for epitope mapping purposes.

[0118] The present invention further includes anti-BCMA antibodies that bind to the same epitope as any of the specific exemplary antibodies described herein (e.g., antibodies comprising any of the amino acid sequences set out in Table 1 herein). Similarly, the present invention also includes anti-BCMA antibodies that compete with any of the specific exemplary antibodies described herein for binding to BCMA (e.g., antibodies comprising any of the amino acid sequences set out in Table 1 herein).

[0119] The present invention also relates to human CD3 and / or and a second antigen binding domain that specifically binds to cynomolgus CD3 and a second antigen binding domain that specifically binds to human BCMA, wherein the second antigen binding domain binds to the same epitope on CD3 as any of the specific exemplary CD3-specific antigen binding domains described herein and / or the second antigen binding domain binds to the same epitope on BCMA as any of the specific exemplary BCMA-specific antigen binding domains described herein.

[0120] Similarly, the present invention also includes bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human BCMA and a second antigen binding domain that specifically binds human CD3, where the first antigen binding domain competes for binding to BCMA with any of the specific exemplary BCMA-specific antigen binding domains described herein and / or the second antigen binding domain competes for binding to CD3 with any of the specific exemplary CD3-specific antigen binding domains described herein.

[0121] Whether a particular antigen-binding molecule (e.g., an antibody) or its antigen-binding domain binds to the same epitope as a reference antigen-binding molecule of the present invention or competes with the reference antigen-binding molecule of the present invention for binding can be easily determined using routine methods known in the art. For example, to determine whether a test antibody binds to the same epitope on BCMA (or CD3) as a reference bispecific antigen-binding molecule of the present invention, the reference bispecific molecule is first bound to a BCMA protein (or CD3 protein). The ability of the test antibody to bind to a BCMA (or CD3) molecule is then evaluated. If the test antibody can bind to BCMA (or CD3) after saturation binding with the reference bispecific antigen-binding molecule, it can be concluded that the test antibody binds to a different epitope of BCMA (or CD3) than the reference bispecific antigen. On the other hand, if the test antibody cannot bind to a BCMA (or CD3) molecule after saturation binding with the reference bispecific antigen-binding molecule, the test antibody may bind to the same epitope of BCMA (or CD3) as the epitope bound by the reference bispecific antigen-binding molecule of the present invention. Further routine experiments (e.g., peptide mutations and binding analysis) can then be performed to confirm whether the observed loss of binding of the test antibody is in fact due to binding to the same epitope as the reference bispecific antigen-binding molecule, or whether steric blocking (or another phenomenon) is responsible for the observed loss of binding. This type of experiment can be performed using ELISA, RIA, Biacore, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art.According to certain embodiments of the invention, two antigen binding proteins bind to the same (or overlapping) epitope if, for example, a 1-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antigen binding protein inhibits binding of the other by at least 50%, but preferably 75%, 90%, or even 99%, as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990:50:1495-1502). Alternatively, two antigen binding proteins are considered to bind the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antigen binding protein reduce or eliminate binding of the other. Two antigen binding proteins are considered to have "overlapping epitopes" if only a subset of amino acid mutations that reduce or eliminate binding of one antigen binding protein reduce or eliminate binding of the other.

[0122] To determine whether an antibody or antigen-binding domain thereof competes with a reference antigen-binding molecule for binding, the above-described binding method is carried out in two orientations. In the first orientation, the reference antigen-binding molecule is allowed to bind to the BCMA protein (or CD3 protein) under saturating conditions, and then the binding of the test antibody to the BCMA (or CD3) molecule is evaluated. In the second orientation, the test antibody is allowed to bind to the BCMA (or CD3) molecule under saturating conditions, and then the binding of the reference antigen-binding molecule to the BCMA (or CD3) molecule is evaluated. In both orientations, If only the first (saturated) antigen-binding molecule can bind to the BCMA (or CD3) molecule, it is concluded that the test antibody and the reference antigen-binding molecule compete for binding to BCMA (or CD3). As will be appreciated by those skilled in the art, an antibody that competes for binding to a reference antigen-binding molecule does not necessarily bind to the same epitope as the reference antibody, but may sterically block the binding of the reference antibody by binding to an overlapping or adjacent epitope.

[0123] Preparation of antigen-binding domains and bispecific molecules Antigen-binding domains specific for a particular antigen can be prepared by any antibody production technique known in the art. Once obtained, two different antigen-binding domains specific for two different antigens (e.g., CD3 and BCMA) can be appropriately arranged with each other to produce the bispecific antigen-binding molecules of the invention using conventional methods. (A discussion of exemplary bispecific antibody formats that can be used to construct the bispecific antigen-binding molecules of the invention is provided elsewhere herein). In certain embodiments, one or more individual components (e.g., heavy and light chains) of the multispecific antigen-binding molecules of the invention are derived from chimeric, humanized or fully human antibodies. Methods for producing such antibodies are well known in the art. For example, one or more heavy and / or light chains of the bispecific antigen-binding molecules of the invention can be prepared using VELOCIMMUNE™ technology. Using VELOCIMMUNE™ technology (or any other human antibody generation technique), high affinity chimeric antibodies against a particular antigen (e.g., CD3 or BCMA) are first isolated with human variable regions and mouse constant regions. Antibodies are characterized and selected for desirable characteristics including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with the desired human constant regions to generate fully human heavy and / or light chains that can be incorporated into the bispecific antigen binding molecules of the invention.

[0124] Genetically engineered animals can be used to generate human bispecific antigen-binding molecules. For example, genetically modified mice can be used that cannot rearrange and express endogenous mouse immunoglobulin light chain variable sequences, and the mice express only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to mouse kappa constant genes at the endogenous mouse kappa locus. Such genetically modified mice can be used to generate fully human bispecific antigen-binding molecules that include two different heavy chains associated with the same light chain that includes a variable domain derived from one of two different human light chain variable region gene segments. (See, for example, US2011 / 0195454). Fully human refers to an antibody, or an antigen-binding fragment thereof, or an immunoglobulin domain that includes an amino acid sequence that is encoded by DNA derived from a human sequence over the entire length of each polypeptide of the antibody, or an antigen-binding fragment thereof, or an immunoglobulin domain. In some examples, the fully human sequence is derived from a protein endogenous to humans. In other examples, a fully human protein or protein sequence includes a chimeric sequence in which each component sequence is derived from a human sequence. Without being bound by any theory, chimeric proteins or sequences are generally designed to minimize the creation of immunogenic epitopes at the junctions of the component sequences, e.g., compared to any wild-type human immunoglobulin region or domain.

[0125] biological equivalent The present invention encompasses antigen binding molecules having amino acid sequences that differ from those of the exemplary molecules disclosed herein, but which retain the ability to bind to CD3 and / or BCMA. Such variant antibodies contain one or more additions, deletions, or substitutions of amino acids compared to the parent sequence, but exhibit biological activity that is essentially equivalent to the biological activity of the bispecific antigen binding molecules described.

[0126] The present invention includes antigen-binding molecules that are biologically equivalent to any of the exemplary antigen-binding molecules described herein.Two antigen-binding proteins or antibodies are considered to be biologically equivalent if, for example, they are pharmaceutical equivalents or pharmaceutical options that do not show significant differences in absorption rate and degree of absorption when administered at the same molar dose, either in single or multiple doses, under similar experimental conditions.Some antigen-binding proteins are to be considered as equivalents or pharmaceutical options when their degree of absorption is equivalent but their absorption rate is not equivalent, and such differences in absorption rate are intentional and reflected in the label, so that they can be considered biologically equivalent, and are considered to be medically significant for the particular drug product tested, for example, not essential to achieve effective body drug concentration for long-term use.

[0127] In one embodiment, two antigen binding proteins are bioequivalent if there are no clinically significant differences in their safety, purity, and efficacy.

[0128] In one embodiment, two antigen binding proteins are bioequivalent if a patient can be switched one or more times compared to therapy sustained without switching between the reference product and the biological product without an expected increase in risk of adverse effects, including clinically significant changes in immunogenicity or reduced efficacy.

[0129] In one embodiment, two antigen binding proteins are biologically equivalent if they both act by a common mechanism or mechanism of action for the condition(s) of use, to the extent that such mechanism is known.

[0130] Bioequivalence may be demonstrated by in vivo and in vitro methods. Bioequivalence measurements include, for example, (a) in vivo studies in humans or other mammals where the concentration of the antibody or its metabolites is measured as a function of time in blood, plasma, serum or other biological fluids, (b) in vitro studies that correlate with and reasonably predict human in vivo bioavailability data, (c) in vivo studies in humans or other mammals where the relevant acute pharmacological effects of the antibody (or its target) are measured as a function of time, and (d) well-controlled clinical trials that establish the safety, efficacy, or bioavailability or bioequivalence of the antigen binding protein.

[0131] Biologically equivalent variants of the exemplary bispecific antigen-binding molecules shown herein can be constructed, for example, by making various substitutions of residues or sequences, or by deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine ​​residues that are not essential for biological activity can be deleted or replaced with other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges during renaturation. In other contexts, biologically equivalent antigen-binding proteins can include variants of the exemplary bispecific antigen-binding molecules described herein, including amino acid changes that modify the glycosylation characteristics of the molecule, such as mutations that eliminate or remove glycosylation.

[0132] Species selectivity and species cross-reactivity According to certain embodiments of the present invention, antigen binding molecules are provided that bind to human CD3 but not to CD3 from other species. Antigen binding molecules that bind to human BCMA but not to BCMA from other species are also provided. The present invention also includes antigen binding molecules that bind to human CD3 and CD3 from one or more non-human species, and / or antigen binding molecules that bind to human BCMA and BCMA from one or more non-human species.

[0133] According to certain exemplary embodiments of the invention, the antibody binds to human CD3 and / or human BCMA and is optionally specific for mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus monkey, marmoset, or the like. Antigen-binding molecules that may or may not bind to one or more of the set, rhesus or chimpanzee CD3 and / or BCMA are provided. For example, in certain exemplary embodiments of the present invention, bispecific antigen-binding molecules are provided that include a first antigen-binding domain that binds to human BCMA and cynomolgus BCMA and a second antigen-binding domain that specifically binds to human CD3, or a first antigen-binding domain that binds to human BCMA and cynomolgus BCMA and a second antigen-binding domain that specifically binds to human CD3.

[0134] Therapeutic Formulations and Administration The present invention provides pharmaceutical compositions comprising the antigen-binding molecules of the present invention. The pharmaceutical compositions of the present invention are formulated with suitable carriers, excipients, and other agents that provide improved transfer, delivery, tolerance, etc. Many suitable formulations can be found in a formulary known to any pharmaceutical chemist: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids (cationic or anionic) containing vesicles (such as LIPOFECTIN™, Life Technologies, Carlsbad, CA), DNA complexes, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.

[0135] The dose of the antigen-binding molecule administered to a patient may vary depending on the age and size of the patient, the target disease, the pathology, the route of administration, and the like. The preferred dose is typically calculated according to body weight or body surface area. When the bispecific antigen-binding molecule of the present invention is used for the purpose of treating an adult patient, it may be advantageous to administer the bispecific antigen-binding molecule of the present invention intravenously, usually at a single dose of about 0.01 to about 20 mg / kg body weight, more preferably at a single dose of about 0.02 to about 7, about 0.03 to about 5, or about 0.05 to about 3 mg / kg body weight. Depending on the severity of the pathology, the frequency and duration of treatment can be adjusted. The effective dosage and schedule for administering the bispecific antigen-binding molecule can be determined empirically, for example, by monitoring the progress of the patient by periodic evaluation and adjusting the dosage accordingly. Furthermore, interspecies scaling of dosage can be performed using methods well known in the art (e.g., Mordenti et al., 1991, Pharmaceut. Res. 8:1351).

[0136] A variety of delivery systems are known and can be used to administer the pharmaceutical compositions of the present invention, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, for example, Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, such as by infusion or bolus injection, absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents. Administration can be systemic or local.

[0137] The pharmaceutical compositions of the present invention can be delivered subcutaneously or intravenously using a standard needle and syringe. In addition, for subcutaneous delivery, a pen delivery device can be used to deliver the pharmaceutical compositions of the present invention. The pen delivery device can be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and easily replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In disposable pen delivery devices, there is no replaceable cartridge. Rather, the disposable pen delivery device is pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0138] Numerous reusable pen and autoinjector delivery devices have application in the subcutaneous delivery of the pharmaceutical compositions of the present invention. Examples include the AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), the DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), the HUMALOG MIX 75 / 25™ pen, the HUMALOG™ pen, the HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), the NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), the NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), the BD™ pen (Becton Dickinson, Franklin Lakes, NJ), the OPTIPEN™, the OPTIPEN PRO™, the OPTIPEN™, the AUTOPEN™, the DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), the HUMALOG MIX 75 / 25™ pen, the HUMALOG™ pen, the HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), the NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), the NOVOPEN™ JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), the BD™ pen (Becton Dickinson, Franklin Lakes, NJ), the OPTIPEN™, ... Examples of disposable pen delivery devices that have application in the subcutaneous delivery of pharmaceutical compositions of the present invention include, but are not limited to, SOLOSTAR pen (Sanofi-Aventis), FLEXPEN (Novo Nordisk), and KWIKPEN (Eli Lilly), SURECLICK autoinjector (Amgen, Thousand Oaks, CA), PENLET (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP) and HUMIRA pen (Abbott Labs, Abbott Park IL).

[0139] In certain circumstances, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, a polymeric material can be used. Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, a sustained-release system can be placed in proximity of the target of the composition, thereby requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, Medical Applications of (See, Controlled Release, supra, vol. 2, pp. 115-138.) Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.

[0140] The injectable preparations may include dosage forms for intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, drip infusion, etc. These injectable preparations may be prepared by publicly known methods. For example, the injectable preparations may be prepared by dissolving, suspending or emulsifying the above-mentioned antibody or its salt in a sterile aqueous medium or oily medium conventionally used for injections. The injection may be prepared by the following steps. Aqueous media for injection include, for example, physiological saline, glucose-containing isotonic solution, and other auxiliary agents, which may be used in combination with suitable solubilizers such as alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)]. As oily media, for example, sesame oil, soybean oil, etc. may be used in combination with solubilizers such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled into a suitable ampoule.

[0141] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into a suitable unit dose dosage form to suit the dose of the active ingredient. Such unit dose dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the antibody contained is generally about 5 to about 500 mg per unit dose dosage form, and particularly in the form of injection, the antibody is preferably contained in an amount of about 5 to about 100 mg, and for other dosage forms, about 10 to about 250 mg.

[0142] Therapeutic Uses of Antigen-Binding Molecules The present invention includes a method comprising administering to a subject in need thereof a therapeutic composition comprising an anti-BCMA antibody or antigen-binding fragment thereof, or a bispecific antigen-binding molecule that specifically binds CD3 and BCMA. The therapeutic composition may comprise any of the antibodies or bispecific antigen-binding molecules disclosed herein and a pharma- ceutically acceptable carrier or diluent. As used herein, the phrase "subject in need thereof" refers to a human or non-human animal that exhibits one or more symptoms or signs of cancer (e.g., a subject that develops a tumor or suffers from any of the cancers described herein below), or who would otherwise benefit from inhibition or reduction of BCMA activity or depletion of BCMA+ cells (e.g., multiple myeloma cells).

[0143] The antibodies and bispecific antigen binding molecules of the present invention (and therapeutic compositions comprising same) are particularly useful for the treatment of any disease or disorder in which stimulating, activating and / or targeting an immune response is beneficial. In particular, the anti-BCMA antibodies or anti-BCMA x anti-CD3 bispecific antigen binding molecules of the present invention can be used for the treatment, prevention and / or amelioration of any disease or disorder associated with or mediated by BCMA expression or activity or proliferation of BCMA+ cells. The mechanism of action by which the therapeutic methods of the present invention are achieved includes the killing of cells expressing BCMA in the presence of effector cells, for example, by CDC, apoptosis, ADCC, phagocytosis, or a combination of two or more of these mechanisms. Cells expressing BCMA that can be inhibited or killed using the bispecific antigen binding molecules of the present invention include, for example, multiple myeloma cells.

[0144] The antigen binding molecules of the present invention can be used to treat diseases or disorders associated with BCMA expression, including, for example, cancers including multiple myeloma or other B-cell or plasma cell cancers, such as Waldenstrom's macroglobulinemia, Burkitt's lymphoma, and diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Hodgkin's lymphoma. According to certain embodiments of the present invention, anti-BCMA antibodies or anti-BCMA x anti-CD3 bispecific antibodies are useful for treating patients suffering from multiple myeloma. According to other related embodiments of the present invention, methods are provided that include administering the anti-BCMA antibodies or anti-BCMA x anti-CD3 bispecific antigen binding molecules disclosed herein to patients suffering from multiple myeloma. Analytical / diagnostic methods known in the art, such as tumor scanning, can be used to ascertain whether a patient is afflicted with multiple myeloma or another B-cell lineage cancer.

[0145] The present invention also includes methods for treating residual cancer in a subject. As used herein, the term "residual cancer" refers to the presence or persistence of one or more cancerous cells in a subject after treatment with an anti-cancer therapy.

[0146] According to certain embodiments, the present invention provides methods for treating a disease or disorder associated with BCMA expression (e.g., multiple myeloma), comprising administering to a subject one or more of the anti-BCMA or bispecific antigen binding molecules described elsewhere herein after the subject has been determined to have multiple myeloma. For example, the present invention includes methods for treating multiple myeloma, comprising administering to a patient an anti-BCMA antibody or an anti-BCMA x anti-CD3 bispecific antigen binding molecule 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, 2 months, 4 months, 6 months, 8 months, 1 year or more after the subject has received other immunotherapy or chemotherapy.

[0147] Combination Therapies and Formulations The present invention provides methods comprising administering a pharmaceutical composition comprising any of the exemplary antibodies and bispecific antigen-binding molecules described herein in combination with one or more additional therapeutic agents. Exemplary additional therapeutic agents that can be administered in combination with or in combination with the antigen-binding molecules of the present invention include, for example, anti-tumor agents (e.g., chemotherapy agents including melphalan, vincristine (Oncovin), cyclophosphamide (Cytoxan), etoposide (VP-16), doxorubicin (Adriamycin), liposomal doxorubicin (Doxil), obendamustine (Treanda), or any other known to be effective in treating plasma cell neoplasms in subjects). In some embodiments, the second therapeutic agent comprises a steroid. In some embodiments, the second therapeutic agent comprises a targeted therapy including thalidomide, lenalidomide, and bortezomib, which are therapies approved for treating newly diagnosed patients. Lenalidomide, pomalidomide, bortezomib, carfilzomib, panobinostat, ixazomib, elotuzumab, and daratumumab are examples of second therapeutic agents that are effective for treating relapsed myeloma. In certain embodiments, the second therapeutic agent is a regimen that includes radiation therapy or stem cell transplantation. In certain embodiments, the second therapeutic agent can be an immunomodulatory agent. In certain embodiments, the second therapeutic agent can be a proteasome inhibitor, including bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro). In certain embodiments, the second therapeutic agent can be a histone deacetylase inhibitor, such as panobinostat (Farydak). In certain embodiments, the second therapeutic agent can be a monoclonal antibody, an antibody drug conjugate, a bispecific antibody conjugated to an antitumor agent, a checkpoint inhibitor, or a combination thereof.Other agents that may be beneficially administered in combination with the antigen-binding molecules of the invention include small molecule cytokine inhibitors and antibodies that bind to cytokines such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13, IL-17, IL-18, or cytokine inhibitors that include their respective receptors. The pharmaceutical compositions of the invention (e.g., pharmaceutical compositions comprising an anti-BCMA x anti-CD3 bispecific antigen-binding molecule as disclosed herein) may also be administered as part of a therapeutic regimen that includes one or more therapeutic combinations selected from monoclonal antibodies other than those described herein that may interact with different antigens on the plasma cell surface, bispecific antibodies having one arm that binds to an antigen on the tumor cell surface and the other arm that binds to an antigen on a T cell, antibody drug conjugates, bispecific antibodies conjugated to an anti-tumor agent, checkpoint inhibitors, such as those that target PD-1 or CTLA-4, or combinations thereof. In certain embodiments, the checkpoint inhibitor may be selected from a PD-1 inhibitor such as pembrolizumab (Keytruda), nivolumab (Opdivo), or cemiplimab (REGN2810). In certain embodiments, the checkpoint inhibitor may be selected from a PD-L1 inhibitor, such as atezolizumab (Tecentriq), avelumab (Bavencio), or durvalumab (Imfinzi). In certain embodiments, the checkpoint inhibitor may be selected from a CTLA-4 inhibitor, such as ipilimumab (Yervoy). Other combinations that can be used in combination with the antibodies of the present invention are described above.

[0148] The present invention also includes therapeutic combinations comprising any of the antigen-binding molecules described herein and one or more inhibitors of VEGF, Ang2, DLL4, EGFR, ErbB2, ErbB3, ErbB4, EGFRvIII, cMet, IGF1R, B-raf, PDGFR-α, PDGFR-β, FOLH1 (PSMA), PRLR, STEAP1, STEAP2, TMPRSS2, MSLN, CA9, uroplakin, or any of the aforementioned cytokines, where the inhibitor is an aptamer, antisense molecule, ribozyme, siRNA, peptibody, nanobody, or antibody fragment (e.g., Fab fragment, F(ab')2 fragment, Fd fragment, Fv fragment, scFv, dAb fragment, or diabody, triabody, tetrabody, minibody, and minimal recognition unit). The antigen-binding molecules of the present invention can also be administered and / or co-formulated in combination with antiviral drugs, antibiotics, analgesics, corticosteroids, and / or NSAIDs. The antigen binding molecules of the present invention may also be administered as part of a treatment regimen that also includes radiation therapy and / or conventional chemotherapy.

[0149] The additional therapeutically active ingredient(s) may be administered immediately prior to, simultaneously with, or immediately following administration of the antigen-binding molecule of the invention. (For purposes of this disclosure, such a dosing regimen will be considered as administering the antigen-binding molecule "in combination" with the additional therapeutically active ingredient.

[0150] The present invention includes pharmaceutical compositions in which an antigen-binding molecule of the invention is co-formulated with one or more of the additional therapeutically active ingredient(s) described elsewhere herein.

[0151] Dosing regimen According to certain embodiments of the invention, multiple doses of an antigen binding molecule (e.g., an anti-BCMA antibody or a bispecific antigen binding molecule that specifically binds to BCMA and CD3) can be administered to a subject over a predetermined period of time. The method according to this aspect of the invention comprises sequentially administering multiple doses of an antigen binding molecule of the invention to a subject. As used herein, "sequentially administering" means that each dose of an antigen binding molecule is administered to a subject at different time points, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The invention includes methods comprising sequentially administering to a patient a single primary dose of an antigen binding molecule, followed by one or more secondary doses of the antigen binding molecule, and then optionally one or more tertiary doses of the antigen binding molecule.

[0152] The terms "primary dose", "secondary dose" and "tertiary dose" refer to the time sequence of administration of the antigen-binding molecule of the present invention. Thus, a "primary dose" is a dose administered at the beginning of a treatment regimen (also called a "baseline dose"); a "secondary dose" is a dose administered after the primary dose; and a "tertiary dose" is a dose administered after the secondary dose. The primary, secondary and tertiary doses may all contain the same amount of antigen-binding molecule, but generally may differ from each other in terms of frequency of administration. However, in certain embodiments, the amount of antigen-binding molecule contained in the primary, secondary and / or tertiary doses differs from each other (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more doses (e.g., two, three, four or five) are administered as a "loading dose" at the beginning of a treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered on a less frequent basis.

[0153] In certain exemplary embodiments of the invention, each secondary and / or tertiary dose is 1 to 26 (e.g., 1, 1 and 1 / 2, 2, 2 and 1 / 2, 3, 3 and 1 / 2, 4, 4 and 1 / 2, 5, 5 and 1 / 2, 6, 6 and 1 / 2, 7, 7 and 1 / 2, 8, 8 and 1 / 2, 9, 9 and 1 / 2, 10, 10 and 1 / 2, 11, 11 and 1 / 2, 12, 12 and 1 / 2, 13 , 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 1 / 2, 25, 25 1 / 2, 26, 26 1 / 2, or more) weeks later. The phrase "immediately preceding dose" as used herein refers to a dose of an antigen binding molecule in a multiple dose series that is administered to a patient prior to administration of the immediately following dose with no intervening doses.

[0154] The method according to this aspect of the invention may include administering any number of secondary and / or tertiary doses of an antigen binding molecule (e.g., an anti-BCMA antibody or a bispecific antigen binding molecule that specifically binds BCMA and CD3) to the patient. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., two, three, four, five, six, seven, eight or more) secondary doses are administered to the patient. Similarly, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., two, three, four, five, six, seven, eight or more) tertiary doses are administered to the patient.

[0155] In embodiments involving multiple secondary doses, each secondary dose may be administered with the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1-2 weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered with the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2-4 weeks after the immediately preceding dose. Alternatively, the frequency with which the secondary and / or tertiary doses are administered to the patient may vary over the course of the treatment regimen. The frequency of administration may also be adjusted by the physician during the course of treatment depending on the needs of the individual patient after clinical testing.

[0156] Diagnostic Uses of Antibodies The anti-BCMA antibodies of the invention may also be used to detect and / or measure BCMA, or BCMA expressing cells, in a sample, e.g., for diagnostic purposes. For example, an anti-BCMA antibody or a fragment thereof may be used to diagnose a condition or disease characterized by aberrant expression of BCMA (e.g., overexpression, underexpression, lack of expression, etc.). An exemplary diagnostic assay for BCMA may include, for example, contacting a sample obtained from a patient with an anti-BCMA antibody of the invention, where the anti-BCMA antibody is labeled with a detectable label or reporter molecule. Alternatively, an unlabeled anti-BCMA antibody may be used in diagnostic applications in combination with a secondary antibody that is itself detectably labeled. The detectable label or reporter molecule may be 3 H, 14 C. 32 P, 35 S or 125 The antibody may be a radioisotope such as I, a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate or rhodamine, or an enzyme such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. 89 For the purpose of non-invasive identification and tracking of tumor cells in a subject, such as Zr-desferrioxamine labeling. 89Zr-labeled antibodies (e.g., positron emission tomography (PET) imaging). (See, e.g., Tavare, R. et al. Cancer Res. 2016 Jan 1;76(1):73-82, and Azad, BB. et al. Oncotarget. 2016 Mar 15;7(11):12344-58.) Certain exemplary assays that can be used to detect or measure BCMA in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting. (FACS) are included.

[0157] Samples that can be used in the BCMA diagnostic assay according to the invention include any tissue or body fluid sample obtainable from a patient that contains a detectable amount of BCMA protein or a fragment thereof under normal or pathological conditions. In general, the level of BCMA in a particular sample obtained from a healthy patient (e.g., a patient not suffering from a disease or condition associated with abnormal BCMA levels or activity) will be measured to first establish a baseline or standard level of BCMA. This baseline level of BCMA can then be compared to the level of BCMA measured in a sample obtained from an individual suspected of having a BCMA-related disease (e.g., a tumor containing BCMA-expressing cells) or condition. EXAMPLES

[0158] The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure.

[0159] Example 1: Generation of anti-BCMA antibodies Anti-BCMA antibodies were obtained by immunizing genetically modified mice with human BCMA antigen (e.g., hBCMA, SEQ ID NO: 115) or by immunizing genetically modified mice containing DNA encoding human immunoglobulin heavy chain and kappa light chain variable regions with human BCMA antigen.

[0160] Following immunization, splenocytes were harvested from each mouse and either (1) fused with mouse myeloma cells to maintain their viability and form hybridoma cells that were screened for BCMA specificity, or (2) B cells were sorted using human BCMA fragments as a sorting reagent that binds and identifies reactive antibodies (antigen-positive B cells) (as described in US2007 / 0280945A1).

[0161] Chimeric antibodies against BCMA with human variable regions and mouse constant regions were first isolated. The antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, etc. If necessary, the mouse constant regions are replaced with the desired human constant regions, e.g., wild-type or modified IgG1 or IgG4 constant regions, to generate fully human anti-BCMA antibodies. The constant regions selected can vary depending on the specific application, but the high affinity antigen binding and target specificity characteristics reside in the variable regions.

[0162] Amino acid and nucleic acid sequences of the heavy and light chain variable regions of anti-BCMA antibodies: Table 1 shows the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-BCMA antibodies of the invention. The corresponding nucleic acid sequence identifiers are shown in Table 2. [Table 1] [Table 2]

[0163] Example 2: Generation of anti-CD3 antibodies The anti-CD3 antibodies were generated as described in WO2017 / 053856, which is incorporated herein by reference. Two such anti-CD3 antibodies were selected from the generation of bispecific anti-BCMA x anti-CD3 antibodies according to the invention. Table 3 shows the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of the selected anti-CD3 antibodies. The corresponding nucleic acid sequence identifiers are shown in Table 4. Other anti-CD3 antibodies for use in the preparation of bispecific antibodies according to the invention can be found, for example, in WO2014 / 047231. [Table 3] [Table 4]

[0164] Example 3: Generation of bispecific antibodies that bind BCMA and CD3 The present invention provides bispecific antigen binding molecules that bind CD3 and BCMA, such bispecific antigen binding molecules are also referred to herein as "anti-BCMA x anti-CD3 or anti-CD3 x BCMA or anti-BCMA x anti-CD3 bispecific molecules." The anti-BCMA portion of the anti-BCMA x anti-CD3 bispecific molecule is useful for targeting tumor cells expressing BCMA (also known as CD269), and the anti-CD3 portion of the bispecific molecule is useful for activating T cells. The simultaneous binding of BCMA on tumor cells and CD3 on T cells promotes direct killing (cytolysis) of the targeted tumor cells by the activated T cells.

[0165] Bispecific antibodies comprising anti-BCMA specific binding domains and anti-CD3 specific binding domains were constructed using standard methods, with the anti-BCMA antigen binding domain and the anti-CD3 antigen binding domain each comprising a different distinct HCVR paired with a common LCVR. In the exemplified bispecific antibody, these molecules were constructed utilizing a heavy chain from an anti-CD3 antibody, a heavy chain from an anti-BCMA antibody, and a common light chain from an anti-CD3 antibody (10082). In other examples, bispecific antibodies may be constructed utilizing a heavy chain from an anti-CD3 antibody, a heavy chain from an anti-BCMA antibody, and a light chain from an anti-CD3 antibody, or antibody light chains that are promiscuous or known to pair effectively with various heavy chain arms. [Table 5]

[0166] Table 6 shows the amino acid sequence identifiers for the bispecific anti-BCMA x anti-CD3 antibodies exemplified herein. [Table 6]

[0167] Example 4: Surface plasmon resonance derived binding affinities and kinetic constants of anti-BCMA antibodies and anti-BCMA x anti-CD3 bispecific antibodies The equilibrium dissociation constants (K DValues) were determined using a real-time surface plasmon resonance biosensor using a Biacore4000 instrument. The CM5 Biacore sensor surface was derivatized by amine coupling with a monoclonal mouse anti-human Fc antibody (GE, #BR-1008-39) to capture purified anti-BCMA mAb and anti-BCMA x anti-CD3 bispecific mAb. All Biacore binding studies were performed in a buffer composed of 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% v / v surfactant P20 (HBS-ET running buffer). For monomer affinity, different concentrations of the extracellular domain of human BCMA expressed with a C-terminal myc-myc-hexahistidine tag (human BCMA-MMH; SEQ ID NO: 106) or monkey BCMA expressed with a C-terminal myc-myc-hexahistidine tag (monkey BCMA-MMH; SEQ ID NO: 110) were prepared in HBS-ET running buffer (90 to 1.11 nM, 3-fold dilutions). For dimer affinity, different concentrations of the extracellular domain of human BCMA expressed with a C-terminal mFc tag (human BCMA-MFC; SEQ ID NO: 108) or monkey BCMA expressed with a C-terminal mFc tag (monkey BCMA-MFC; SEQ ID NO: 112) were prepared in HBS-ET running buffer (30 to 0.37 nM, 3-fold dilutions) or 30 nM BCMA expressed with a C-terminal mFc tag (mouse BCMA-MFC; SEQ ID NO: 114) were prepared. Antigen samples were then injected over the surface captured anti-BCMA and anti-BCMA x anti-CD3 bispecific mAbs at a flow rate of 30 μL / min. Antibody-reagent binding was monitored for 5 min while dissociation was monitored for 10 min in HBS-ET running buffer. All binding kinetic experiments were performed at 25°C. Kinetic binding (k a ) rate constant and kinetic dissociation (k d The binding / dissociation equilibrium constant (K D ) and dissociation half-life (t1 / 2) were calculated from the kinetic rate constants as follows:

number

[0168] As shown in Table 7, at 25°C, all anti-BCMA antibodies of the invention had a cytotoxicity of 1.06 nM to 3 K in the range of .56 nM D As shown in Table 8, at 25° C., all anti-BCMA antibodies of the invention bound to human BCMA-MMH with K values ​​ranging from 22.3 pM to 103 pM. D As shown in Table 9, at 25°C, the two anti-BCMA antibodies of the invention bound to human BCMA-MFC with K values ​​ranging from 38.8 nM to 49.92 nM. D As shown in Table 10, at 25° C., the four anti-BCMA antibodies of the invention bound to monkey BCMA-MMH with K values ​​ranging from 148 pM to 14.7 nM. D As shown in Table 11, at 25° C., the four anti-BCMA antibodies of the invention bound to monkey BCMA-MFC with K values ​​ranging from 677 pM to 18.8 nM. D The antibody bound to mouse BCMA-MFC with a value of 0.01. [Table 7] [Table 8] [Table 9] [Table 10] [Table 11]

[0169] Example 5: FACS binding of anti-BCMA x anti-CD3 bispecific antibodies to human and cynomolgus CD3 expressing cells Using flow cytometry analysis, human and cynomolgus CD3 (Jurkat cells, mfCD3 engineered Jurkat cells, primary human CD8+ and cynomolgus CD8+ The binding of BCMAxCD3 bispecific antibodies to BCMAxCD3 T cells was determined. Briefly, 1e05 cells / well were incubated for 30 min on ice in the presence of a FACS wash with block (PBS+1% filtered FBS+5% mouse serum) with serial dilutions of BCMAxCD3 and control antibodies. After incubation, cells were washed twice with cold FACS wash (PBS+1% filtered FBS) and bound antibodies were detected by incubating with an anti-human secondary antibody conjugated with Alexa647 for another 30 min on ice. Wells containing no antibody or only secondary antibody were used as controls. To detect monkey and human T cells, a cocktail of human and cynomolgus cross-reactive antibodies against CD4, CD8, and CD16 was added to the anti-human secondary antibody. After incubation, cells were washed and resuspended in 200 μL cold PBS containing 1% filtered FBS and analyzed on a BD FACS Canto II. Cells were gated by FSC-A to select singlet events, followed by side scatter and forward scatter to select live events. For monkey T cells, additional gating was performed on CD8+ / CD16- cells.

[0170] EC50 values ​​for FACS binding were calculated using four-parameter nonlinear regression analysis in Prism software.

[0171] Jurkat cells are a human CD3 expressing T cell lymphoblastoid cell line. REGN5458 has a median EC50 of 1.50 x 10 -8 M and 3.20×10 -8 REGN5459 bound to human CD3 on Jurkat cells and primary human CD8+ T cells bearing M. Binding of REGN5459 was weak to human CD3, with a median EC50 of 5.58 × 10 on Jurkat cells. -7 M and 4.71 × 10 for primary human CD8 T cells. -6Using CRISPR / Cas9 technology, Jurkat cell lines were engineered to express cynomolgus monkey CD3ε and CD3δ chains instead of the human versions. The median EC50 for binding of REGN5458 to the mfCD3 engineered Jurkat cell lines was 1.51x10 -8 M and its median EC50 for binding to primary cynomolgus monkey CD8+ T cells was 4.66 × 10 -8 M. REGN5459 did not bind to mfCD3 expressing cells.

[0172] No binding was observed in any cell line with a negative isotype control antibody, designated mAb15260. [Table 12]

[0173] Example 6: FACS binding assay to evaluate cell surface antigen binding capacity The ability of the anti-BCMA x CD3 antibody, mAb25442D, to bind to the surface of BCMA-positive multiple myeloma (NCI-H929, MM.1S, OPM-2, and RPMI-8226), BCMA-positive lymphoma (Raji and Daudi), and BCMA-negative (HEK293) cells was determined by flow cytometry. Cells were harvested from flasks using cell dissociation buffer (Millipore, catalog no. S-004-C) and plated at a density of 500,000 cells per well in 96-well V-bottom plates in staining buffer (PBS, calcium and magnesium free (Irving 9240) + 2% FBS (ATCC 30-2020). Cells were incubated at 4°C for 30 min with Alexa647 conjugates. Cells were stained for 30 min at 4°C with two-fold serial dilutions of a conjugated anti-BCMAxCD3 antibody (mAb25442D-A647) or an Alexa647-conjugated isotype control with the same CD3-binding arm paired with an irrelevant tumor-targeting arm (isotype-A647). Cells were washed twice with staining buffer and labeled with the LIVE / DEAD™ Fixable Green dead cell staining kit (Invitrogen, L34970) according to the manufacturer's instructions to distinguish live from dead cells. Cells were then washed and fixed for 25 min at 4°C using a 50% solution of BD Cytofix (BD, Cat. No. 554655) diluted in PBS. Samples were run on an Accuri C6 flow cytometer (BD Biosciences) and analyzed with Flowjo 10.2 (Tree Star). After gating for live and single cells, mean fluorescence intensity (MFI) was determined and MFI values ​​were calculated based on the EC 50 A four-parameter logistic equation was used on the 10-point response curves to calculate EC. The zero condition of each dose-response curve was also included in the analysis as a succession of 2-fold serial dilutions and is represented as the lowest dose. Signal-to-noise ratios (S / N) were determined by taking the ratio of mAb25442D-A647 MFI to Isotype-A647 MFI (Table 13). The S / N for mAb25442D-A647 ranged from 2 to 470 and was plotted in Graphpad Prism. 50 Values ​​ranged from 27 to 83 nM. No detectable binding was observed in HEK293 cells. [Table 13]

[0174] Example 7: T cell activation via bispecific anti-BCMA x anti-CD3 antibodies in the presence of BCMA-expressing cells The activity of anti-BCMA x anti-CD3 bispecific antibodies was assessed in a Jurkat / NFATLuc reporter bioassay utilizing several cell lines with different levels of BCMA surface expression. Jurkat cells were engineered to express an NFAT-luciferase reporter (Jurkat / NFATLuc.3C7), and 50,000 Jurkat reporter cells were mixed with 50,000 BCMA-positive (Daudi, MM1-S, NCI-H929, OPM-2, RPMI-8226, MOLP-8, or Raji) or BCMA-negative (HEK293) cells in 50ul of assay medium (RPMI medium with 10% FBS and 1% P / S / G) in Thermo Nunclon Delta 96-well white microwell plates (Thermo Scientific, catalog no. 136102). Three-fold serial dilutions of BCMAxCD3 bispecific antibodies (mAb25441D or mAb25442D) or bivalent anti-BCMA antibody (mAb21581) were immediately added in 50uL of assay buffer. Plates were gently agitated and incubated for 4-6 hours in a 37°C, 5% CO2 incubator. NFAT-luciferase activity was determined using Promega One-Glo (cat# E6130) and a Perkin Elmer Envision plate reader. RLU The E.C. 50 To calculate values, a four-parameter logistic equation was used on the 12-point response curves plotted in GraphPad Prism. The no antibody treatment condition for each dose-response curve was also included in the analysis as a succession of 3-fold serial dilutions and is represented as the lowest dose. Signal-to-noise ratio (S:N) was determined by taking the ratio of the highest RLU to the lowest RLU on the curve.

[0175] mAb25441D activated Jurkat / NFATLuc cells in the presence of BCMA-expressing cells with EC50s ranging from 0.61 nM to 2.1 nM and S:Ns ranging from 8 to 123. mAb25442D activated Jurkat / NFATLuc cells in the presence of BCMA-expressing cells with EC50s ranging from 2.6 nM to 11 nM and S:Ns ranging from 7 to 120. The BCMA×CD3 bispec mAb25441D with its high affinity CD3 binding arm was consistently more potent than mAb25442D with its low affinity CD3 binding arm, while the S:Ns were similar for the two bispecifics. Neither antibody activated Jurkat / NFATLuc cells in the presence of HEK293 cells, and the control bispecific antibody did not significantly increase Jurkat reporter activity in any of the cell lines tested. The results are shown below in Tables 14A and 14B. [Table 14] [Table 15]

[0176] Example 8: FACS-based cytotoxicity assay to assess T cell-mediated killing of BCMA-expressing multiple myeloma cells in the presence of anti-BCMA x anti-CD3 bispecific antibodies. The antibody binding capacity (ABC) of a commercially available anti-human BCMA antibody (clone 19F2) was determined on a panel of multiple myeloma cell lines using the Quantum Simply Cellular anti-human IgG kit according to the manufacturer's instructions (Bangs Laboratories).

[0177] Briefly, multiple myeloma (MM) cell lines (H929, MM1S, U266, MOLP8, and RPMI8226) and Quantum Simply Cellular beads were incubated with titrations of APC-conjugated anti-hBCMA-19F2 antibodies for 30 minutes at 4° C. After incubation, cells and beads were washed three times, resuspended in 200 μL cold PBS containing 1% filtered FBS, and analyzed by flow cytometry. Using the QuickCal® template (Bangs Labs), saturation levels of anti-BCMA 19F2 ABC for each cell line were interpolated from a standard curve generated by the channel intensity of the bead population at saturation.

[0178] Killing of BCMA-expressing target cells by resting human or cynomolgus T cells was determined by flow cytometry. Briefly, human or cynomolgus peripheral blood mononuclear cells (PBMCs) were cultured at 1 × 10 6 Cells were seeded at 1000 cells / mL in supplemented RPMI (human) or X-Vivo (cynomolgus) medium and incubated overnight at 37°C to enrich for lymphocytes by depleting adherent macrophages, dendritic cells, and some monocytes. The following day, BCMA-expressing target cells were labeled with 1uM Violet CellTrace and co-cultured at 37°C with adherent cell-depleted PBMCs (effector / target cell 4:1 ratio) and serial dilutions of BCMAxCD3 bispecific or control antibodies. After 48-72 hours, cells were removed from the cell culture plate, stained with cocktail phenotypic antibodies and live / dead cell viability dyes, and analyzed by FACS. To quantify the number of live target cells present in the well, 20μl of CountBright absolute counting beads were added to the well immediately prior to acquisition. To assess the specificity of killing, cells were gated on the Violet CellTrace labeled population. Target cell viability was calculated as follows: target viability = (R1 / R2) * 100, where R1 = absolute number of live target cells in the presence of effector cells and antibody, and R2 = number of live target cells only (cultured without effector cells or test antibody).

[0179] Human CD8+ T cells were gated as CD45+ / CD14- / CD4- / CD8+. Cynomolgus CD8+ T cells were gated as CD45+ / CD20- / CD14- / CD4- / CD8+, and T cell activation was reported as the percentage of CD25+ or CD69+ T cells among total CD8+ T cells.

[0180] EC50 values ​​for target cell survival and T cell activation were calculated using four-parameter nonlinear regression analysis in Prism software.

[0181] The anti-BCMA x anti-CD3 bispecific antibody was tested for its ability to activate resting human and cynomolgus T cells to kill a panel of BCMA-expressing cells differing in surface BCMA levels. Using resting human T cells as effector cells, REGN5458 mediated the killing of five different BCMA cell lines and EC 50 The value is 7.07 x 10 -10 M~3.45×10 -11 REGN5459 demonstrated killing of the same five cell lines with an EC50 value of 1.66 × 10 -9 M~1.06×10 -10 M range. EC 50 is dying EC 50 Moderate T cell activation was observed in the presence of the one-arm CD3 isotype control mAb 17664D, but only in the U266 cell line. No cytotoxicity was observed with any of the isotype controls tested.

[0182] BCMA×CD3-mediated killing by cynomolgus T cells was only tested in the MM cell line H929. EC 50 are 2.34×10 -11 and 6.92 × 10 -11No cytotoxicity or T cell activation was observed with the isotype control antibody mAb15260 using human or cynomolgus monkey effector cells. The results are shown in Tables 15A, 15B, and 16 below. [Table 16] [Table 17] [Table 18]

[0183] Example 9: FACS cytotoxicity assay for autologous T cell-mediated killing of primary multiple myeloma blast cells in the presence of anti-BCMA x anti-CD3 bispecific antibodies To monitor specific killing of multiple myeloma cells by flow cytometry, bone marrow mononuclear cells (BMMCs) from multiple myeloma patients were seeded onto human stromal cells (HS5) and rested overnight at 37°C. Separately, peripheral blood mononuclear cells (PBMCs) from matched patients were thawed and cultured at 1 × 10 for lymphocyte enrichment by depletion of adherent cells. 6 BMMCs were cultured overnight at 37 °C in supplemented RPMI medium at 1000 cells / mL. The next day, BMMCs were co-cultured at 37 °C with adherent cell-depleted naïve PBMCs on stromal cells (HS5) and serial 10-fold dilutions of BCMA x CD3 bispecific or one-arm CD3 isotype control (starting concentration 66.7 nM). On days 3, 4, or 7, cells were removed from the cell culture plates and analyzed by FACS. To assess the specificity of killing, multiple myeloma cells were gated as single, live, CD90 negative (except for stromal cells), CD2 negative, CD56 positive. CD45 was low in multiple myeloma cells in most samples except MM455. For calculation of adjusted viability, the percentage of live target cells was reported as follows: adjusted viability = (R1 / R2) * 100, where R1 = percentage of live target cells in the presence of antibody (%), and R2 = percentage of live target cells in the absence of test antibody (%).

[0184] T cells were gated as CD2 positive, CD56 negative, and CD4 positive or CD8 positive. T cell activation was reported as the percentage of CD25+CD4 or CD8 T cells among total CD4 or CD8 T cells.

[0185] BCMAxCD3 bispecific antibodies were tested for their ability to redirect killing of primary multiple myeloma blasts by autologous donor PBMCs. Maximal BCMAxCD3-mediated cytotoxicity of primary MM blasts ranged from 52 to 96%, with an EC50 of 9.89 x 10 for REGN5458. -11 M~3.67×10 -9 M ranges from 4.96 x 10 for REGN5459. -10 M~7.94×10 -8 M. T cell activation was measured by assessing the upregulation of CD25 on CD8+ T cells. The EC50 for T cell activation was 3.23 × 10 -9 ~1.69×10 -10 Moderate cytotoxicity and T cell activation was observed with the one-arm CD3 (non-target binding) isotype control. The results are shown in Tables 17A and 17B below. [Table 19] [Table 20]

[0186] Example 10: Anti-BCMA x anti-CD3 bispecific antibodies prevent the growth of BCMA-expressing tumors (NCI-H929) in vivo in a xenogeneic tumor model To determine the in vivo efficacy of a BCMAxCD3 bispecific antibody (Ab), a xenogeneic tumor study was performed. scid Il2rg tm1Wjl / SzJ(NSG) mice, 10 × 10 6 BCMA-expressing NCI-H929 multiple myeloma cells and 0.5 x 10 isolated from normal donors 6A mixture of 10000 cells / mL of human peripheral blood mononuclear cells (PBMCs) was implanted subcutaneously. Mice (n=7 per group) were immediately dosed with PBS vehicle control, irrelevant anti-FelD1 bivalent isotype control Ab (REGN2759), CD3-binding control bispecific Ab (mAb17664D), BCMAxCD3 (G;REGN5458) bispecific Ab, or BCMAxCD3 (G20;REGN5459) bispecific Ab at a dose of 4 mg / kg. Mice were dosed with Abs twice weekly for a total of 3 weeks, and tumor growth was assessed over a 40-day period. BCMA + Tumors grew similarly in vehicle, isotype control, and CD3 binding control treated mice, whereas BCMA × CD3 All three Abs prevented tumor growth in vivo.

[0187] Syngeneic tumor implantation and measurement: NSG mice were implanted with 10 × 10 6 BCMA-expressing NCI-H929 multiple myeloma cells and 0.5 × 10 derived from normal donors 6 A mixture of 1000 PBMCs was implanted subcutaneously. Mice (n=7 per group) were immediately dosed with PBS vehicle control, irrelevant anti-FelD1 bivalent isotype control Ab (REGN2759), CD3-binding control bispecific Ab (mAb17664D), BCMAxCD3 (G;REGN5458) bispecific Ab, or BCMAxCD3 (G20;REGN5459) bispecific Ab at a dose of 4 mg / kg. Mice were dosed with Ab twice weekly for a total of 3 weeks. Tumor growth was measured twice weekly with calipers for the duration of the experiment. Mice were sacrificed 40 days after tumor implantation.

[0188] Calculation of syngeneic tumor growth and inhibition: To determine tumor volume with external calipers, the maximum major axis (length in mm) and maximum transverse axis (width in mm) were determined. Based on the caliper measurements, tumor volume was calculated according to the formula: Volume (mm 3 )=(length x width 2 ) / 2.

[0189] BCMA×CD3 bispecific Ab inhibits BCMA in vivo in xenogeneic tumor models +The growth of NCI-H929 tumors was prevented. The results are shown in Table 18 below. [Table 21-1] [Table 21-2] [Table 21-3] [Table 21-4] [Table 21-5] [Table 21-6] [Table 21-7] [Table 21-8]

[0190] Example 11: Anti-BCMAxAnti-CD3 Bispecific Antibody Prevents the Growth of BCMA-Expressing Tumors (NCI-H929) in a Dose-Dependent Manner in a Xenogeneic In Vivo Tumor Model To determine the in vivo efficacy of anti-BCMAx anti-CD3 bispecific antibodies (Abs), xenogeneic tumor studies were performed. scid Il2rg tm1Wjl / SzJ(NSG) mice, 10 × 10 6 BCMA-expressing NCI-H929 human multiple myeloma cells and 0.5 x 10 isolated from normal healthy donors 6The mixture was implanted subcutaneously with human peripheral blood mononuclear cells (PBMCs). Mice (n=7 per group) were then immediately administered PBS vehicle control, CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 4 mg / kg, CD3-binding control bispecific Ab (G20; REGN4460) at a dose of 4 mg / kg, BCMA×CD3 (G; REGN5458) bispecific Ab at a dose of either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg, or BCMA×CD3 (G20; REGN5459) bispecific Ab at a dose of either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg. Mice were administered these Abs twice weekly for a total of seven doses, and tumor growth was evaluated over a 60-day period. BCMA + NCI-H929 tumors grew similarly in mice treated with vehicle and CD3 binding control, but both anti-BCMA x anti-CD3 Abs tested prevented tumor growth in a dose-dependent manner in vivo.

[0191] Xenograft tumor implantation and measurement: NSG mice were implanted with 10 × 10 6 BCMA-expressing NCI-H929 multiple myeloma cells and 0.5 × 10 derived from normal healthy donors 6 Mice (n=7 per group) were immediately dosed with PBS vehicle control, CD3 binding control bispecific Ab (G; mAb17664D), CD3 binding control bispecific Ab (G20; REGN4460), BCMA×CD3 (G; REGN5458) bispecific Ab, or BCMA×CD3 (G20; REGN5459) bispecific Ab. mAb17664D and REGN4460 were dosed at 4 mg / kg, but not RE. GN5458 and REGN5459 were administered at either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg. Mice were administered Ab twice weekly for a total of seven doses. Tumor growth was measured twice weekly with calipers for the duration of the experiment.

[0192] Calculation of xenograft tumor growth and inhibition: To determine tumor volume with external calipers, the maximum major axis (length in mm) and maximum transverse axis (width in mm) were determined. Based on the caliper measurements, tumor volume was calculated according to the formula: Volume (mm 3 )=(length x width 2 ) / 2.

[0193] The BCMAxCD3 bispecific Ab inhibited BCMA in a dose-dependent manner in this heterogeneous in vivo tumor model. + The results are shown in Table 19 below and illustrated in Figures 1 and 2. [Table 22-1] [Table 22-2] [Table 22-3] [Table 22-4] [Table 22-5] [Table 22-6] [Table 22-7] [Table 22-8] [Table 22-9] [Table 22-10] [Table 22-11] [Table 22-12] [Table 22-13] [Table 22-14]

[0194] Example 12: Anti-BCMA x anti-CD3 bispecific antibodies reduce the size and prevent the growth of established BCMA-expressing tumors (NCI-H929) in a dose-dependent manner in a xenogeneic in vivo tumor model To determine the in vivo efficacy of anti-BCMAx anti-CD3 bispecific antibodies (Abs), xenogeneic tumor studies were performed. scid Il2rg tm1Wjl / SzJ(NSG) mice, 10 × 10 6 BCMA-expressing NCI-H929 human multiple myeloma cells and 0.5 x 10 isolated from normal healthy donors 6 A mixture of 100 human peripheral blood mononuclear cells (PBMCs) was implanted subcutaneously. The tumors were approximately 70 mm in size. 3 The mice were allowed to grow and establish for 5 days until they were fully grown. Then, on day 5, mice (n=7-8 per group) were administered PBS vehicle control, CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 4 mg / kg, CD3-binding control bispecific Ab (G20; REGN4460) at a dose of 4 mg / kg, BCMA×CD3 (G; REGN5458) bispecific Ab at either a dose of 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg, or BCMA×CD3 (G20; REGN5459) bispecific Ab at either a dose of 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg. The Abs were administered twice weekly for a total of seven doses, and tumor growth was assessed over a 55-day period. + NCI-H929 tumors grew similarly in mice treated with vehicle and CD3 binding control, but both BCMAxCD3 Abs tested shrank established tumors and prevented tumor growth in a dose-dependent manner in vivo.

[0195] Xenograft tumor implantation and measurement: NSG mice were implanted with 10 × 10 6 BCMA-expressing NCI-H929 multiple myeloma cells and 0.5 × 10 derived from normal healthy donors 6 The mixture of 1000 and 1000 PBMCs was implanted subcutaneously. The tumors were approximately 70 mm in size. 3 Tumors were allowed to grow and establish for 5 days until tumors were fully established. Then, on day 5, mice (n=7-8 per group) were immediately dosed with PBS vehicle control, CD3-binding control bispecific Ab (G; mAb17664D), CD3-binding control bispecific Ab (G20; REGN4460), BCMA×CD3 (G; REGN5458) bispecific Ab, or BCMA×CD3 (G20; REGN5459) bispecific Ab. mAb17664D and REGN4460 were dosed at 4 mg / kg, whereas REGN5458 and REGN5459 were dosed at either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg. Mice were dosed with Ab twice weekly for a total of 7 doses. Tumor growth was measured twice weekly with calipers for the duration of the experiment.

[0196] Calculation of xenograft tumor growth and inhibition: To determine tumor volume with external calipers, the maximum major axis (length in mm) and maximum transverse axis (width in mm) were determined. Based on the caliper measurements, tumor volume was calculated according to the formula: Volume (mm 3 )=(length x width 2 ) / 2.

[0197] Anti-BCMA x anti-CD3 bispecific antibodies demonstrated a dose-dependent inhibition of BCMA in this heterogeneous in vivo tumor model. + The results are shown in Table 20 below and in Figures 3 and 4. [Table 23-1] [Table 23-2] [Table 23-3] [Table 23-4] [Table 23-5] [Table 23-6] [Table 23-7] [Table 23-8] [Table 23-9] [Table 23-10] [Table 23-11]

[0198] Example 13: Anti-BCMA x anti-CD3 bispecific antibodies prevent the growth of BCMA-expressing tumors (MOLP-8) in a dose-dependent manner in a xenogeneic in vivo tumor model To determine the in vivo efficacy of anti-BCMA x anti-CD3 bispecific antibodies (Abs), a xenogeneic tumor study was performed. scid Il2rg tm1Wjl / SzJ(NSG) mice, 5 × 10 6 1 x 10 BCMA-expressing MOLP-8 human multiple myeloma cells isolated from normal healthy donors 6The mixture was implanted subcutaneously with human peripheral blood mononuclear cells (PBMCs). Mice (n=7 per group) were then immediately administered PBS vehicle control, CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 4 mg / kg, CD3-binding control bispecific Ab (G20; REGN4460) at a dose of 4 mg / kg, BCMA×CD3 (G; REGN5458) bispecific Ab at a dose of either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg, or BCMA×CD3 (G20; REGN5459) bispecific Ab at a dose of either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg. Mice were administered these Abs twice weekly for a total of seven doses, and tumor growth was evaluated over a period of 56 days. BCMA + MOLP-8 tumors in mice treated with vehicle and CD3 binding control Although grown similarly, both BCMAxCD3 Abs tested prevented tumor growth in a dose-dependent manner in vivo.

[0199] Xenograft tumor implantation and measurement: NSG mice were implanted with 5 × 10 6 BCMA-expressing MOLP-8 multiple myeloma cells and 1 × 10 derived from normal healthy donors 6 A mixture of mAb17664D and PBMCs was implanted subcutaneously. Mice (n=7 per group) were immediately dosed with PBS vehicle control, CD3-binding control bispecific Ab (G; mAb17664D), CD3-binding control bispecific Ab (G20; REGN4460), BCMA×CD3 (G; REGN5458) bispecific Ab, or BCMA×CD3 (G20; REGN5459) bispecific Ab. mAb17664D and REGN4460 were dosed at 4 mg / kg, whereas REGN5458 and REGN5459 were dosed at either 4 mg / kg, 0.4 mg / kg, or 0.04 mg / kg. Mice were dosed with Ab twice weekly for a total of seven doses. Tumor growth was measured by caliper twice weekly for the duration of the experiment.

[0200] Calculation of xenograft tumor growth and inhibition: To determine tumor volume with external calipers, the maximum major axis (length in mm) and maximum transverse axis (width in mm) were determined. Based on the caliper measurements, tumor volume was calculated according to the formula: Volume (mm 3 )=(length x width 2 ) / 2.

[0201] The anti-BCMA × anti-CD3 bispecific antibody inhibited BCMA in a dose-dependent manner in this heterogeneous in vivo tumor model. + The results are shown in Table 21 below and in Figures 5 and 6. [Table 24-1] [Table 24-2] [Table 24-3] [Table 24-4] [Table 24-5] [Table 24-6] [Table 24-7] [Table 24-8] [Table 24-9] [Table 24-10] [Table 24-11] [Table 24-12] [Table 24-13]

[0202] Example 14: Anti-BCMA x anti-CD3 bispecific antibodies slow the growth of BCMA-expressing tumors (MOLP-8) in a xenographic in vivo tumor model. To determine the in vivo efficacy of anti-BCMA x anti-CD3 bispecific antibodies (Abs), a xenograft tumor study was performed. scid Il2rg tm1Wjl / SzJ(NSG) mice were cultured with 4 × 10 6 Human peripheral blood mononuclear cells (PBMCs) were injected intraperitoneally. On day 0, mice were injected with 2 × 10 PBMCs engineered to also express firefly luciferase (MOLP-8-luciferase cells). 6 BCMAs + MOLP-8 human multiple myeloma tumor cells were administered intravenously. Mice (n=5 per group) were then immediately administered either a CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 4 mg / kg or a BCMA×CD3 (G; REGN5458) bispecific Ab at a dose of 4 mg / kg. Mice were administered these Abs two more times on days 3 and 7 for a total of three doses. Tumor growth was assessed over a 48-day period by measuring tumor bioluminescence (BLI) in anesthetized animals. As a positive control, a group of mice (n=5) received only MOLP-8-luciferase cells and no PBMCs or antibodies. To measure background BLI levels, a group of mice ( n=5) were untreated and did not receive tumor, PBMC, or antibody. + MOLP-8-luciferase tumors grew progressively in CD3-binding control-treated mice, but BCMAxCD3Ab treatment with REGN5458 slowed tumor growth in vivo.

[0203] Xenograft tumor engraftment and measurement: On day 11, immunodeficient NOD.Cg-Prkdc scid Il2rgtm1Wjl / SzJ(NSG) mice were intraperitoneally administered 5 × 10 6 On day 0, mice were injected with 2 × 10 6 BCMAs + MOLP-8-luciferase cells were administered intravenously. Mice (n=5 per group) were then immediately administered either a CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 4 mg / kg or a BCMA×CD3 (G; REGN5458) bispecific Ab at a dose of 4 mg / kg. Mice were administered these Abs two more times on days 3 and 7 for a total of three doses. Tumor growth was assessed over a 48-day period by measuring tumor BLI in anesthetized animals. As a positive control, a group of mice (n=5) received only MOLP-8-luciferase cells and no PBMCs or antibodies. To measure background BLI levels, a group of mice (n=5) was left untreated and did not receive tumor, PBMCs, or antibodies.

[0204] Measurement of heterogeneous tumor growth: Tumor burden was measured using BLI imaging. Mice were injected IP with 150 mg / kg of the luciferase substrate D-luciferin suspended in PBS. Five minutes after this injection, BLI imaging of mice was performed under isoflurane anesthesia using a Xenogen IVIS system. Image collection was performed with a field of view at D, a subject height of 1.5 cm, and medium binning level with automatic exposure time determined by the Living Image software. BLI signal was extracted using Living Image software: a region of interest was drawn around each cell volume and photon intensity was recorded as p / s / cm2 / sr.

[0205] The anti-BCMA x anti-CD3 bispecific antibody REGN5458 inhibited BCMA in this heterogeneous in vivo tumor model. + The growth of MOLP-8-luciferase tumors was delayed. The results are shown in Table 22 below. [Table 25-1] [Table 25-2] [Table 25-3] [Table 25-4] [Table 25-5] [Table 25-6] [Table 25-7] [Table 25-8] [Table 25-9] [Table 25-10]

[0206] Example 15: Anti-BCMA x anti-CD3 bispecific antibody reduces tumor (OPM-2) burden to background levels in vivo To determine the in vivo efficacy of anti-BCMA x anti-CD3 bispecific antibodies (Abs), a xenograft tumor study was performed. On day 0, immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ(NSG) mice were transfected with 2 × 10 6 BCMAs + Mice were administered OPM-2 human multiple myeloma tumor cells intravenously. On day 10, mice were administered 4 × 10 6Human peripheral blood mononuclear cells (PBMCs) were injected intraperitoneally. On day 21, mice (n=5 per group) were administered CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 0.4 mg / kg, BCMA×CD3 (G; REGN5458) bispecific Ab at 0.4 mg / kg, or BCMA×CD3 (G20; REGN5459) bispecific Ab at 0.4 mg / kg. Mice were administered these Abs two more times on days 25 and 28 for a total of three doses. Tumor growth was assessed over a 61-day period by measuring tumor bioluminescence (BLI) in anesthetized animals. As a positive control, a group of mice (n=5) received only OPM-2-luciferase cells and no PBMCs or antibodies. To measure background BLI levels, a group of mice (n=5) was left untreated and did not receive tumor, PBMCs, or antibodies. BCMA + OPM-2-luciferase tumors grew slowly in mice treated with the CD3 binding control, whereas BCMA × CD3 Ab treatment with REGN5458 and REGN5459 significantly increased the size of the animals. Many reduced tumor burden to background levels.

[0207] Xenograft tumor engraftment and measurement: On day 0, immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ(NSG) mice were transfected with 2 × 10 6 BCMAs + Mice were administered OPM-2 human multiple myeloma tumor cells intravenously. On day 10, mice were administered 4 × 10 6Human peripheral blood mononuclear cells (PBMCs) were injected intraperitoneally. On day 21, mice (n=5 per group) were administered CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 0.4 mg / kg, BCMA×CD3 (G; REGN5458) bispecific Ab at 0.4 mg / kg, or BCMA×CD3 (G20; REGN5459) bispecific Ab at 0.4 mg / kg. Mice were administered these Abs two more times on days 25 and 28 for a total of three doses. Tumor growth was assessed over a 61-day period by measuring tumor bioluminescence (BLI) in anesthetized animals. As a positive control, a group of mice (n=5) received only OPM-2-luciferase cells and no PBMCs or antibodies. To measure background BLI levels, a group of mice (n=5) was left untreated and did not receive tumor, PBMCs, or antibodies.

[0208] Measurement of heterogeneous tumor growth: Tumor burden was measured using BLI imaging. Mice were injected IP with 150 mg / kg of the luciferase substrate D-luciferin suspended in PBS. Five minutes after this injection, BLI imaging of mice was performed under isoflurane anesthesia using a Xenogen IVIS system. Image collection was performed with a field of view at D, a subject height of 1.5 cm, and medium binning level with automatic exposure time determined by the Living Image software. BLI signal was extracted using Living Image software: a region of interest was drawn around each cell volume and photon intensity was recorded as p / s / cm2 / sr.

[0209] BCMA + OPM-2-luciferase tumors grew slowly in mice treated with the CD3 binding control, but BCMAxCD3 Ab treatment with REGN5458 and REGN5459 reduced tumor burden to background levels in the majority of animals. The results are shown in Table 23 below and depicted in Figure 7. [Table 26-1] [Table 26-2] [Table 26-3] [Table 26-4] [Table 26-5] [Table 26-6] [Table 26-7] [Table 26-8] [Table 26-9] [Table 26-10] [Table 26-11]

[0210] Example 16: BCMAxCD3 bispecific antibodies suppress syngeneic tumor growth in vivo in a dose-dependent manner To determine the in vivo efficacy of anti-BCMA x anti-CD3 bispecific antibodies (Abs), syngeneic tumor studies were performed in mice expressing human CD3. C57BL / 6 mice expressing human CD3deg instead of mouse CD3deg (CD3-humanized mice) were injected with 0.5 × 10 6 1 × 10 B16 melanoma cells or 1 × 10 engineered to express full-length human BCMA (MC38 / BCMA) 6Mice (n=7 per group) were then immediately administered either CD3 binding control bispecific Ab (G; mAb17664D) at a dose of 0.4 mg / kg or BCMA×CD3 (G; REGN5458) bispecific Ab at doses of 0.4 mg / kg or 0.04 mg / kg. Mice were administered these Abs two more times on days 4 and 7 for a total of three doses, and tumor growth was assessed throughout the experiment. B16 / BCMA and MC38 / BCMA tumors grew in CD3 binding control treated mice, whereas BCMA×CD3 REGN5458 was able to suppress the growth of both tumor lines in a dose-dependent manner in vivo.

[0211] Implantation and measurement of syngeneic tumors: 0.5 x 10 cells engineered to express full-length human BCMA (B16 human / BCMA cells) into C57BL / 6 mice expressing human CD3deg in place of mouse CD3deg (CD3-humanized mice). 6 1 × 10 B16F10 melanoma cells or 1 × 10 engineered to express full-length human BCMA (MC38 / BCMA) 6 MC38 colon cancer cells were subcutaneously implanted in mice. Mice (n=7 per group) were then immediately administered either a CD3-binding control bispecific Ab (G; mAb17664D) at a dose of 0.4 mg / kg or a BCMA×CD3 (G; REGN5458) bispecific Ab at a dose of 0.4 mg / kg or 0.04 mg / kg. Mice were administered these Abs two or more times on days 4 and 7 for a total of three doses, and tumor growth was assessed throughout the experiment.

[0212] Calculation of syngenic tumor growth and inhibition: To determine tumor volume by external calipers, the maximum major axis (length in mm) and maximum transverse axis (width in mm) were determined. Based on the caliper measurements, tumor volume was calculated according to the formula: Volume (mm 3 )=(length x width 2 ) / 2.

[0213] While B16 / BCMA and MC38 / BCMA tumors grew in CD3 conjugate control treated mice, BCMAxCD3 REGN5458 was able to suppress the growth of both tumor lines in a dose-dependent manner in vivo. The results are shown in Table 24 below. [Table 27-1] [Table 27-2] [Table 27-3] [Table 27-4]

[0214] Example 17: Epitope Mapping of REGN5458 Binding to BCMA by Hydrogen-Deuterium Exchange H / D exchange epitope mapping by mass spectrometry (HDX-MS) was performed to determine the amino acid residues of BCMA (recombinant human BCMA, amino acid sequence of SEQ ID NO: 115) that interact with REGN5458 (BCMAxCD3 bispecific antibody). A general description of the H / D exchange method is described, for example, in Ehring (1999) Analytical Biochemistry 267(2):252-259, and Engen and Smith (2001) Anal.Chem.73:256A-265A.

[0215] HDX-MS experiments were performed on an integrated HDX / MS platform, consisting of a Leaptec HDX PAL system for deuterium labeling and quenching, a Waters Acquity M-Class (Auxiliary) for sample digestion and loading. The equipment consisted of a Waters Acquity M-Class (μBinary solvent manager) for analytical gradients, a Waters Acquity M-Class (μBinary solvent manager) for analytical gradients, and a Thermo Q Exactive HF mass spectrometer for peptide mass measurements.

[0216] Labeling solutions were prepared as PBS buffer in DO at pD7.0 (10 mM phosphate buffer, 140 mM NaCl, and 3 mM KCl, equivalent to pH 7.4 at 25° C.). For deuterium labeling, 10 μL of hBCMA.hFc (REGN2746, 54.5 μM; hBCMA.hFc premixed with SEQ ID NO:120 or REGN5458 at a molar ratio of 1:2 (Ag-Ab complex)) was incubated with 90 μL of DO labeling solution at 20° C. at various time points during the replicates (e.g., non-deuterated control=0 seconds, 5 minutes, and 10 minutes deuterium labeled). Deuteration reactions were quenched by adding 100 μL of pre-chilled quench buffer (0.5 M TCEP-HCl, 8 M urea, and 1% formic acid) to each sample and incubated at 20° C. for 5 minutes. The quenched samples were then injected into a Waters HDX Manager for online pepsin / protease XIII digestion. The digested peptides were purified using a C8 column (1.0 The peptides were separated using a 13 min gradient from 10% to 32% B (mobile phase A: 0.5% formic acid in water, mobile phase B: 0.1% formic acid in acetonitrile) on a 100-well column (10 mm × 50 mm, NovaBioassays). Eluted peptides were analyzed by Q Exactive HF mass spectrometry in LC-MS / MS or LC-MS mode.

[0217] LC-MS / MS data of non-deuterated BCMA samples were searched against a database containing BCMA and its randomized sequences using the Byonic search engine (Protein Metrics). Search parameters (ELN) were set as default with non-specific enzymatic digestion and human glycosylation as general variable modifications. The list of identified peptides was then imported into HDX Workbench software (version 3.3) to calculate the deuterium uptake of each peptide detected by LC-MS from all deuterated samples. For a given peptide, the centroid mass (intensity-weighted average mass) at each time point was used to calculate deuterium uptake (D) and percentage of deuterium uptake (D(%)). [Table 28]

[0218] A total of eight peptides from hBCMA.hFc were identified from both hBCMA.hFc alone and hBCMA.hFc complexed with REGN5458 samples, representing 100% sequence coverage of hBCMA. The mean standard deviation (SD) of all peptides was assessed to be 1.4% (detailed calculations defined in ELN and Pascal, BD et al (2012) Journal of the American Society for Mass Spectrometry 23(9):1512-1521). Thus, any peptide that showed a different percentage of D uptake values ​​greater than 4.2% (three times the mean SD) was defined as significantly protected. In the case of hBCMA.hFc, the peptide corresponding to amino acids 1-43 of SEQ ID NO:106 (MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNA; SEQ ID NO:121) was significantly protected by REGN5458. Protection of these residues by REGN5458 was confirmed using hBCMA.mmH (REGN2744, amino acid sequence of SEQ ID NO: 106). [Table 29]

[0219] Example 18: Against multiple myeloma cell lines after overnight incubation with anti-BCMA antibodies FACS binding assay of BCMA×CD3 bispecific antibodies and additional BCMA antibodies Flow cytometry analysis was utilized to determine the effect of overnight incubation of multiple myeloma cell lines with anti-BCMA antibodies on the levels of surface BCMA. MM cell lines (H929, Molp8, U266, and MM1.S) were washed twice and cultured at 37°C in R10 medium (RPMI+10% FBS+pen / strep / glut) containing 66.7 or 667 nM anti-BCMA antibodies, DAPT (gamma secretase inhibitor), or medium alone. After 18 hours, wells were washed with cold FACS wash (PBS+1% filtered FBS) and resuspended in 667 nM of the same anti-BCMA antibodies in cold staining buffer (Miltenyi 130-091-221) for 30 minutes on ice. After incubation, cells were washed twice with cold FACS wash (PBS + 1% filtered FBS) and bound antibodies were detected by incubating for an additional 30-45 min with the appropriate anti-human secondary antibody (anti-hIgG or anti-HIS) on ice. After incubation, cells were washed, resuspended in 200 µL of cold PBS containing 1% filtered FBS and analyzed by flow cytometry on a BD FACS Canto II. Fold increase in staining was calculated by dividing the MFI of stained cells previously incubated overnight with BCMA ab or DAPT by the MFI of stained cells incubated overnight in media alone.

[0220] BCMA is rapidly cleaved from the surface of cells by the enzyme gamma-secretase. Overnight incubation with a gamma-secretase inhibitor such as DAPT prevents BCMA cleavage and increases BCMA levels on the cell surface. Tables 26-29 report the fold increase in median fluorescence intensity (MFI) of BCMA in cells incubated overnight with anti-BCMA antibodies or DAPT compared to cells incubated in media alone. We observed that overnight incubation with DAPT increased BCMA levels detected by anti-BCMA antibodies (BCMA x CD3 bispecific R5458, parent BCMA antibody mAb15281, and other in-house BCMA antibodies) by 2.3-4 fold, 2.4-8.6 fold, 5.3-9.0 fold, and 11.9 fold in H929, Molp8, U266, and MM.1S, respectively.

[0221] Of note, overnight incubation of MM cell lines with 66.7 or 667 nM REGN5458 or the parental bivalent anti-BCMA antibody mAb21581 was observed to similarly increase the levels of surface BCMA as detected by FACS, suggesting that binding of the anti-BCMA antibodies prevents cleavage of BCMA by gamma secretase. The antibodies induced an increase in surface BCMA that varied depending on the cell line, with a further fold increase in Molp8 and MM1S cells compared to H929 or U266. This phenomenon was not limited to REGN5458, as it was also observed with other in-house BCMA antibodies. [Table 30] [Table 31] [Table 32] [Table 33]

[0222] Example 19: Autologous T cell-mediated killing of human and cynomolgus monkey plasma cells in the presence of BCMAxCD3 bispecific antibodies Enriched CD138 on unstimulated autologous T cells + Specific killing of human or cynomolgus monkey plasma cells was assessed by flow cytometry. Human or cynomolgus monkey bone marrow aspirates and blood were donated within 24 hours of collection. + Plasma cells were transfected using EasySep Human CD138 + Bone marrow was enriched by positive selection using a positive selection kit. PBMCs from whole blood were isolated by density separation. PBMCs were labeled with 1 μM Vybrant CFDA-SE fluorescent tracking dye. After labeling, 1 × 10 4 Enrichment of CD138 + Plasma cells were seeded in round-bottom 96-well plates at an E:T ratio of 10:1 with Vybrant CFDA-SE-labeled PBMCs and serial dilutions of REGN5458, CD3-binding control bsAb, or BCMA-binding control mAb in complete medium for 72 h at 37°C. At the end of culture, viable CD138 + Plasma cells were analyzed by flow cytometry utilizing fixable LIVE / DEAD dye and plasma cell specific cell surface markers. Viability was normalized to control conditions (plasma cells in the presence of PBMCs only). T cell activation was assessed by flow cytometry. Activation was assessed by CD25 expressing CD2 + / CD4 + or CD2 + / CD8 + / CD16 - Reported as percentage of T cells. Percentage of T cell activation was normalized to control conditions (plasma cells in the presence of PBMCs only).

[0223] In vitro studies evaluated the effect of REGN5458 or a negative control (BCMA-binding control mAb or CD3-binding control bsAb) on primary human and cynomolgus monkey T cell activation and autologous plasma cell cytotoxicity. EC50 The values ​​are summarized in Table 30.

[0224] REGN5458 mediated cytotoxicity of primary human plasma cells from donors 1 and 2 in the presence of autologous T cells in a concentration-dependent manner, EC 50 The values ​​were 42.8 pM and 191 pM, respectively, with maximum percentage cytotoxicity of 91% and 89%, respectively. In parallel, REGN5458 mediated T cell activation in a concentration-dependent manner in the presence of human plasma cells from donors 1 and 2, and CD8 + ECs in T cell activation 50 The values ​​were 214 pM and 860 pM, respectively, and CD8 + The maximum percentage of T cell activation was 2% and 36%, respectively. Plasma cell cytotoxicity in both donors and CD8 + Increased T cell activation was observed with nanomolar concentrations of the CD3 binding control. No cytotoxicity or effect on T cell activation was observed with the BCMA binding control at any of the concentrations tested in either donor.

[0225] REGN5458 mediated cytotoxicity of primary cynomolgus monkey plasma cells in a concentration-dependent manner in both donors, with an EC 50 was calculated for donor 1, whereas EC 50 The effect of REGN5458 on plasma cell cytotoxicity could not be determined. In both donors, treatment with REGN5458 increased plasma cell cytotoxicity (maximal percentage of cytotoxicity in donors 1 and 2 was 94% and 91%, respectively). In parallel, REGN5458 mediated T cell activation in a concentration-dependent manner in the presence of cynomolgus monkey plasma cells from donors 1 and 2, and CD4 + EC for T cell activation 50 The values ​​are 28 .1nM and 18.1nM, and CD8 + EC for T cell activation 50 The values ​​were 22.4 nM and 76.7 nM. The resulting maximum percentage of T cell activation was observed in donors 1 and 2, where CD4+ In T cells, the percentages were 9% and 16%, respectively, and in CD8 + In T cells, the figures were 12% and 17%, respectively.

[0226] No target cell killing was observed with the BCMA-binding control at any concentration tested in any of the cell lines evaluated. Some target cell killing and T cell activation in the presence of plasma cells from donor 2 was observed with the CD3-binding control at nanomolar concentrations. [Table 34]

[0227] Example 20: Anti-BCMA x anti-CD3 bispecific antibodies act synergistically with anti-PD-1 antibodies to enhance anti-tumor effects in vivo To determine whether BCMAxCD3 bispecific antibodies (Abs) synergize with PD-1 blockade to provide superior antitumor efficacy in vivo, syngeneic tumor studies were performed in mice expressing human CD3. Results show that the combination of REGN5458 and PD-1 blockade provides superior antitumor efficacy than either REGN5458 or PD-1 blockade alone.

[0228] Implantation and measurement of syngeneic tumors: 1 × 106 cells engineered to express full-length human BCMA (MC38 / BCMA) in C57BL / 6 mice expressing human CD3deg in place of mouse CD3deg (CD3-humanized mice). 6 MC38 colon cancer cells were implanted subcutaneously. Tumors were allowed to establish for 3 days, at which point mice (n=6 or 7 per group) were administered either a surrogate anti-mouse PD-1 antibody (clone RPM1-14) at 4 mg / kg, or an isotype control Ab (clone 2A3) at 4 mg / kg, along with a CD3-binding control bispecific Ab (G; H4sH17664D) at a dose of 0.4 mg / kg, and BCMA×CD3 (G; REGN5458) at a dose of 0.04 mg / kg or 0.24 mg / kg. Specific treatment groups are shown in Table 31 below. [Table 35]

[0229] Mice were administered these Abs two more times on days 7 and 11 for a total of three doses, and tumor growth was assessed throughout the experiment.

[0230] Calculation of syngenic tumor growth and inhibition: To determine tumor volume by external calipers, the maximum major axis (length in mm) and maximum transverse axis (width in mm) were determined. Based on the caliper measurements, tumor volume was calculated according to the formula: Volume (mm 3 )=(length x width 2 ) / 2.

[0231] The results indicate that the combination of REGN5458 and PD-1 blockade provides superior anti-tumor efficacy than either REGN5458 or PD-1 blockade alone. Notably, the results showed that on day 24 (the last day data was collected for all treatment groups), the combination of BCMAxCD3 bispecific antibody and anti-PD-1 antibody provided a statistically significant synergistic therapeutic effect in inhibiting tumor growth (Table 32, 0.04 mg / kg BCMAxCD3 and 4 mg / kg anti-PD-1). On day 24, using a 2-way ANOVA, p<0.0001 between (i) the combination of REGN5458 (0.04 mg / kg) + isotype and REGN5458 (0.04 mg / kg) + anti-PD-1 antibody (group 3 vs. group 4), (ii) the combination of REGN5458 (0.24 mg / kg) + isotype and REGN5458 (0.24 mg / kg) + anti-PD-1 antibody (group 5 vs. group 6), and (iii) the combination of anti-PD-1 and REGN5458 (0.04 mg / kg) + anti-PD-1 antibody (group 2 vs. group 6). On day 24, using a 2-way ANOVA, p=0.0005 between the combination of anti-PD-1 and REGN5458 (0.04 mg / kg) + anti-PD-1 antibody (group 2 vs. group 4). Increasing the dose of BCMAxCD3 bispecific antibody (0.24 mg / kg) in combination with PD-1 blockade resulted in tumor inhibition comparable to lower doses of bispecific antibody and PD-1 blockade in this experiment. The demonstrated synergy with low doses of bispecific antibody is advantageous because the use of lower doses reduces the risk of adverse side effects. Similarly, the combination of BCMAxCD3 bispecific antibody with anti-PD-1 antibody showed synergistic therapeutic effects at both doses of bispecific antibody (0.04 mg / kg and 0.24 mg / kg) in the number of tumor-free mice at the end of the experiment (day 28), as shown in Table 33. [Table 36-1] [Table 36-2] [Table 36-3] [Table 36-4] [Table 36-5] [Table 36-6] [Table 36-7] [Table 36-8] [Table 37]

[0232] Example 21: Anti-BCMA x anti-CD3 bispecific antibodies act synergistically with anti-PD-1 antibodies to enhance anti-tumor effects in vivo Similar results were obtained in a second experiment, identical to those discussed above in Example 20, except that the number of mice per group was 10 and the high dose of BCMAxCD3 REGN5458 was 0.4 mg / kg. The specific treatment groups in the second experiment are shown in Table 34 below. [Table 38]

[0233] The results indicate that the combination of REGN5458 and PD-1 blockade provides superior anti-tumor efficacy than either REGN5458 or PD-1 blockade alone. Notably, the results showed that on day 21 (the last day data was collected for all treatment groups), the combination of BCMAxCD3 bispecific antibody and anti-PD-1 antibody provided synergistic therapeutic efficacy in inhibiting tumor growth (Table 35, BCMAxCD3 at 0.04 mg / kg and anti-PD-1 at 4 mg / kg). On day 21, using a two-way ANOVA, the results showed that the combination of (i) REGN5458 (0.04 mg / kg) + isotype vs. REGN5458 (0.04 mg / kg) + anti-PD-1 antibody combination (group 3 vs. group 4), (ii) anti-PD-1 and REGN5458 (0.0 p<0.0001 between (iii) the combination of anti-PD-1 and REGN5458 (0.4mg / kg) + anti-PD-1 antibody (group 2 vs. group 4), and (iv) the combination of anti-PD-1 and REGN5458 (0.4mg / kg) + anti-PD-1 antibody (group 2 vs. group 6). As discussed above in Example 20, increasing the dose of BCMAxCD3 bispecific antibody (0.4mg / kg) in combination with PD-1 blockade provided tumor inhibition comparable to low doses of bispecific antibody in combination with PD-1 blockade in this experiment. The demonstrated synergy with low doses of bispecific antibody is advantageous because the use of low doses reduces the risk of adverse side effects. Similarly, the combination of BCMAxCD3 bispecific antibody and anti-PD-1 antibody showed synergistic therapeutic effects at both doses of bispecific antibody (0.04mg / kg and 0.4mg / kg) in the number of tumor-free mice at the end of the experiment (day 25), as shown in Table 36. [Table 39-1] [Table 39-2] [Table 39-3] [Table 39-4] [Table 39-5] [Table 39-6] [Table 39-7] [Table 40]

[0234] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to be included within the scope of the appended claims.

Claims

1. 1. An isolated bispecific antigen-binding molecule comprising: (a) a first antigen-binding domain comprising a heavy chain variable region (HCVR) comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:66, and comprising HCDR1, HCDR2, and HCDR3 domains, the first antigen-binding domain comprising the amino acid sequences of SEQ ID NOs:68, 70, and 72, respectively, and a light chain variable region (LCVR) comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:82, and comprising LCDR1, LCDR2, and LCDR3 domains, the first antigen-binding domain comprising the amino acid sequences of SEQ ID NOs:84, 86, and 88, respectively, the first antigen-binding domain specifically binding to human B-cell maturation antigen (BCMA); and (b) a second antigen-binding domain comprising an HCVR comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 90, and comprising HCDR1, HCDR2, and HCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 92, 94, and 96, respectively, and an LCVR comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 82, and comprising LCDR1, LCDR2, and LCDR3 domains comprising the amino acid sequences of SEQ ID NOs: 84, 86, and 88, respectively, and which specifically binds to human CD3; The isolated bispecific antigen-binding molecule comprising:

2. 1. An isolated bispecific antigen-binding molecule comprising: (a) a first antigen-binding domain comprising a heavy chain variable region (HCVR) comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:66, and comprising HCDR1, HCDR2, and HCDR3 domains, the first antigen-binding domain comprising the amino acid sequences of SEQ ID NOs:68, 70, and 72, respectively, and a light chain variable region (LCVR) comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:82, and comprising LCDR1, LCDR2, and LCDR3 domains, the first antigen-binding domain comprising the amino acid sequences of SEQ ID NOs:84, 86, and 88, respectively, the first antigen-binding domain specifically binding to human B-cell maturation antigen (BCMA); and (b) an HCVR comprising an HCDR1, HCDR2, and HCDR3 domain, each of which comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:98 and each of which comprises the amino acid sequences of SEQ ID NOs:100, 102, and 104, respectively; and an HCVR comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:82 and each of which comprises the amino acid sequences of SEQ ID NOs:84, 86, and 88, respectively. a second antigen-binding domain that specifically binds to human CD3 and that comprises an LCVR that comprises LCDR1, LCDR2, and LCDR3 domains; The isolated bispecific antigen-binding molecule comprising:

3. (a) a first antigen-binding domain comprising an HCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 66, and an LCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 82; and (b) a second antigen-binding domain comprising an HCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 90, and an LCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 82; 2. The isolated bispecific antigen-binding molecule of claim 1 , comprising:

4. (a) a first antigen-binding domain comprising an HCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 66, and an LCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 82; and (b) a second antigen-binding domain comprising an HCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 98, and an LCVR comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 82; 3. The isolated bispecific antigen-binding molecule of claim 2, comprising:

5. 5. The isolated bispecific antigen-binding molecule of claim 1, which is a bispecific antibody.

6. (a) the bispecific antibody comprises a human IgG heavy chain constant region; optionally, the human IgG heavy chain constant region is of isotype IgG1 or IgG4; and / or (b) the bispecific antibody comprises a chimeric hinge that has reduced Fcγ receptor binding compared to a wild-type hinge of the same isotype.

6. The isolated bispecific antigen-binding molecule of claim 5.

7. A pharmaceutical composition comprising the bispecific antigen-binding molecule of any one of claims 1 to 6 and a pharma- ceutically acceptable carrier or diluent.

8. A nucleic acid molecule comprising a nucleotide sequence encoding the bispecific antigen-binding molecule of any one of claims 1 to 6, or a group of nucleic acid molecules comprising a nucleotide sequence encoding the HCVR of the first antigen-binding domain, the HCVR of the second antigen-binding domain, and the LCVR of the first and second antigen-binding domains, respectively, of the bispecific antigen-binding molecule of any one of claims 1 to 6.

9. An expression vector comprising a nucleic acid molecule according to claim 8 or a group of expression vectors each comprising a group of nucleic acid molecules according to claim 8.

10. A host cell comprising a bispecific antigen-binding molecule according to any one of claims 1 to 6, a nucleic acid molecule or a group of nucleic acid molecules according to claim 8, or an expression vector or a group of expression vectors according to claim 9.

11. The pharmaceutical composition of claim 7 for inhibiting the growth of a plasma cell neoplasm in a subject.

12. The pharmaceutical composition of claim 11, wherein the plasma cell neoplasm is multiple myeloma.

13. Treating patients with multiple myeloma or another BCMA-expressing B cell malignancy The pharmaceutical composition according to claim 7.

14. 14. The pharmaceutical composition of claim 13, wherein the BCMA-expressing B-cell malignancy is selected from the group consisting of Waldenstrom's macroglobulinemia, Burkitt's lymphoma, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Hodgkin's lymphoma.

15. 15. The pharmaceutical composition of any one of claims 11-14, for use in combination with a second therapeutic agent or treatment regimen; optionally, the second therapeutic agent or treatment regimen comprises a chemotherapeutic agent, a DNA alkylating agent, an immunomodulatory agent, a proteasome inhibitor, a histone deacetylase inhibitor, radiation therapy, stem cell transplantation, different bispecific antibodies interacting with different tumor cell surface antigens and T cell or immune cell antigens, an antibody drug conjugate, a bispecific antibody conjugated to an anti-tumor agent, a PD-1, PD-L1, or CTLA-4 checkpoint inhibitor, or a combination thereof.

16. The pharmaceutical composition of claim 7, in combination with an anti-PD-1 antibody or antigen-binding fragment thereof, for treating a patient suffering from a BCMA-expressing tumor.

17. 17. The pharmaceutical composition of claim 16, wherein the anti-PD-1 antibody or antigen-binding fragment is an anti-PD-1 antibody; and optionally, the anti-PD-1 antibody is cemiplimab (REGN2810).

Citation Information

Patent Citations

  • Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

    WO2014047231A1

  • Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof

    WO2017031104A1

  • Bi specific Anti-MUC16-CD3 antibodies and NTI-MUC16 drug conjugates

    WO2018067331A1